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1. Introduction 
1.1. Epigenetics 
The human body is buildup of over 200 diverse kinds of cell types, yet all share the genomic 
DNA sequence as an almost identical genetic blueprint.1 This genetic information is heritable 
and passed on to the next generation after cell division. Even though all cells arise from the 
same stem cell, one genotype can result in different phenotypes. This further implies that 
genes determining the phenotype are permanently turned on while others are switched off. 
This pattern of active and inactive genes is stably kept and transferred to the new cell. When 
this phenomenon was discovered, the question was raised whether additional information is 
passed on to the daughter cell beyond the canonical DNA-sequence.  
Conrad Waddington proposed in the early 1940s the term of “epigenetics”.2 He coined this 
term as a variety of developmental processes above the level of the genome.3 Mechanisms 
by which the genotype of a cell emerges into several special phenotypes. Waddington knew 
these developmental processes were separate from the genome and he was able to bridge 
the gap between genotype and phenotype.4 If an organism is fully developed its overall 
genome remains stable, apart from random mutations. The functional determination, which 
part of the genome is transcribed and therefore which genes are expressed are based on 
several mechanisms. For instance, biochemical modifications at single DNA bases or histone 
modifications determine the accessibility of the DNA. 
More than 60 years ago, it was discovered that cytosine (C) deoxynucleotides could carry 
methyl groups (5-methyl cytosine, 5mC) in eukaryotic genomic DNA. Since then, 5mC has 
been intensively studied for its role as carrier of epigenetic information. In 1975 two key 
publications on 5mC as well as X-chromosome inactivation due to methylation events, 
demonstrated that the modification of C could serve as an epigenetic mark.5,6 In their work 
Holliday, Pugh and Riggs suggested that the DNA sequence could be methylated de novo and 
that this mark could be passed on during cell division while the additional information is 
stored in the form of methyl groups on the DNA itself (see figure 1). They speculated that DNA 
binding proteins could sense and interpret the presence of methyl groups in the DNA. 
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Moreover, the methylation of the DNA could directly silence a gene which would bring the 
phenotype of a cell into being.7 
 
 
Figure 1: Differentiation between genetics and epigenetics. A mutation is a change in the setup of the DNA and 
might result from imperfect DNA replication. Epigenetics on the other hand are reversible and based on 
alterations of gene expression or the accessibility of the gene.  
 
1.1 Methylation of Cytosine 
Today methylation of the 5th position of Cytosine is one of the best studied epigenetic 
modifications. 5mC is the most common modification in vertebrates. In mammalian cells this 
epigenetic mark predominantly appears in so called CpG dinucleotides.7 Regions with high 
CpG density at transcription starting sites (TSS) are shown to have an influence on gene 
control, e.g. methylation on TSS can block initiation of the DNA polymerase while the 
methylation on the gene body itself does not impair transcription.7 Other studies of targeted 
de novo methylation and demethylation revealed that genes can be switched from their 
expressed to their silenced state and vice versa.8 Another function of 5mC is to maintain the 
stability of the genome. Methylation of cytosine in repeat regions like centromeres are 
considered important for chromosomal stability due to suppression of transposons.9 Due to 
this manifold involvement in cellular processes, 5mC is an important factor to keep cellular 
processes functional. In normal cells, CpG islands are usually not methylated. In contrast, 
tumor cells exhibit global hypo-methylation of DNA. This loss of epigenetic modifications 
leads to methylation deficiency in repetitive DNA sequences, causing silent CpGs to become 
active. Moreover, coding regions as well as introns exhibit reduced methylation which finally 
results in chromosomal and therefore genomic instability. This further causes the reactivation 
of transposable elements and favors meiotic recombination.10,11 Along with the overall 
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hypo-methylation of tumor DNA, hyper-methylated tumor suppressor genes were identified. 
10 In contrast to normal cells, tumor suppressor genes become hyper-methylated which 
results in the silencing of gene expression. In this major event of cancer development many 
genes can be affected which play a significant role in cell cycle control, apoptosis as well as 
DNA repair. A known example for hyper-methylation of a tumor suppressor gene is the breast 
cancer susceptibility gene 1 (BRCA1) and its consequential inactivation in the development of 
breast cancer. 11 Taken together, 5mC plays a major role in regulation of gene expression and 
maintaining the genome stability.12  
DNA methylation is part of a complex epigenetic network. Next to the modification of DNA, 
other epigenetic events are involved. For example, histone proteins do not only function in 
DNA packaging but their molecular structure can influence gene expression. Here, the 
epigenetic information is stored on the histone in form acetylation of lysine (K), methylation 
of K and arginine (R), as well as phosphorylation of serine (S). These modifications are post-
translational introduced to the histone tails and can be in a single, double or even triple 
fashion, e.g. histone 3 can be single methylated at lysine residue 3 (H3K3me) which leads to 
activation of transcription.10 These modifications on the histone proteins influence gene 
transcription and DNA repair. However, this “histone code” is very complex and it is difficult 
to predict the outcome of a modification event, since the functional consequences do not rely 
on a single modification but on the interplay of several modifications. While acetylation is in 
general associated with activation, the outcome of methylation events depends on the 
targeted amino acid and the residue position within the histone tail. E.g. methylation at H3K9 
and H3K20 in combination with H4K20 leads to the repression of gene transcription.13–16 In 
cancer cells, the histones exhibit a different pattern of methylation and acetylation compared 
to normal cells. Hence, the common interplay of histone modifications might be disrupted in 
cancer cells. 
 
Epigenetic signals are reversible. The mechanism to introduce and remove, as well as 
maintain epigenetic marks involves participation of DNA-methyltransferases (DMT) and 
Demethylases. In DNA, DMTs are essential for setting up methylation patterns and catalyze 
the methylation of C to 5mC using S-adenosyl methionine (SAM) as methyl donor.17 For a long 
time it was believed that passive dilution of 5mC based on replication of the cell and absence 
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of methylation maintenance is the only pathway for demethylation of 5mC.18 However, with 
the identification of oxidized 5mC species (5-hydroxymethyl cytosine, hmC; 5-formyl cytosine, 
fC and 5-carboxy ctyosine, caC) an active demethylation mechanism in mammalians was 
proposed. In this active demethylation pathway 5mC is oxidized to hmC by the ten-eleven 
translocation dioxygenase 1 (TET1).19–21 Further oxidation of hmC by TET leads to fC and caC, 
which are used as a substrate for the thymine-DNA-glycosylase (TDG).19,20,22,23 In this step, 
TDG creates abasic sites which can be restored to C via base excision repair (see figure 2 ).8,24,25 
While hmC is the most stable and abundant epigenetic modification of the cytosine derivates 
known so far, the overall genomic content is variable depending on the cell type. The 
abundance of fC and caC shows a far lower frequency than 5mC and hmC. Despite their roles 
in the active demethylation pathway, the involvement of the oxidized variants in other 
biochemical processes is yet unclear 24,26–31. 
 
 
Figure 2: Methylation of cytosine by DMT and active demethylation of 5mC via the TET enzyme to higher oxidized 
modifications. fC and caC are catalyzed to their abasic from by TDG and are further restored to cytosine by base 
excision repair (BER) 32 
11 
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1.2 Adenine Methylation in Prokaryotic Genomes 
Based on its widespread distribution the most common and best studied DNA modification in 
eukaryotes is 5mC. It exerts a dominant function by establishing the epigenetic setting and by 
playing a putative role in DNA-based physiological disorders like cancer. However, 5mC is 
mostly absent in prokaryotic genomes. By contrast, N6-methyl adenine (6mA) is the most 
dominant epigenetic mark in bacteria. 6mA entails many functions in the prokaryotic cell and 
methylation of A in E. coli occurs via the DNA adenine methyltransferase (Dam). Embedded 
in the sequence context of GATC, Dam transfers a methyl group to the adenine amino group 
using S-adenosyl methionine (SAM) as a methyl donor. The leftover S-adenosyl-homocysteine 
(SAH) is regenerated to SAM in an ATP-dependent reaction (see figure 3).33 The Dam enzyme 
is the first methyltransferase (MTase) identified in γ-proteobacteria. It is classified as a SAM-
dependent α-MTase. Based on a 10 amino acids domain, Dam shares significant homology 
with DpnIIA and MboIA methyltransferases. The Dam MTase is widespread in enteric bacteria 
and can be found e.g. in Salmonella spp., Yersinia spp. and Vibrio cholerae.33 Commonly, 
methylation occurs after DNA replication. The replication fork passes the methylation site 
trailed by Dam which processes hemi- and unmethylated GATC with similar efficiency.34 Since 
the Dam enzyme can be a de novo or a maintenance MTase, 6mA acts as a transient or stable 
epigenetic mark depending on the event.34,35 
 
 
Figure 3: The DNA nucleobase adenosine (A) is modified to its epigenetic version of N6-methyl-adenosine (6mA) 
by the transfer of a methyl group. This transfer is performed by methyltransferases and can be reversible. Image 
from 36 
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1.2.1 Adenine Methylation during DNA Replication 
6mA is involved in sister-strand synthesis in E. coli. Only in the presence of methylated 
adenine at the origin of replication (oriC) the initiator protein DnaA binds and separates the 
two DNA strands.37 During DNA replication, GATC sites of oriC are not immediately fully 
methylated but remain hemi-methylated for a major part of the cell cycle. Consequently, the 
newly synthesized DNA does not carry 6mA as a signal and de novo methylation is hindered 
by the protein named SeqA, which negatively regulates initiation of DNA replication. This 
hemi-methylated state of the oriC prevents the start of a new replication cycle.35,38 
Additionally, the discrimination of non-methylated daughter strands enables E. coli to employ 
the methylated parental strand as a template for mismatched DNA bases guided by 
recognition of the MutHLS protein complex.39  
 
1.2.2 Adenine Methylation for Genome Defense 
6mA functions as signal for genome defense embedded in the restriction-
modification-system (RM). The RM-system is believed to be evolved protecting bacteria 
against bacteriophages and can be found in many prokaryotic and archaeal life forms. It 
distinguishes between host DNA and foreign invader DNA.40 The RM-system encodes pairs of 
intracellular enzyme activities: An endonuclease and its opposing partner DNA 
methyltransferase.41 The endonuclease cleaves invading viral DNA at short recognition sites 
which are not modified by methylation. Meanwhile, the host DNA is protected by 6mA. The 
unmodified invading DNA is rarely methylated fast enough to be protected from restriction 
and thus the RM-system provides a simple form of genome protection along with self and 
non-self-discrimination (see figure 4).33 
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Figure 4: Functions of adenine methylation in prokaryotic genomes. 6mA plays a role in the protection of the 
genome against viruses. Also, it is involved in DNA replication, sister strand synthesis and the repair of 
mismatched DNA. The establishment of pathogenic virulence and adhesins expression via phase variation are 
also 6mA mediated. Image is adapted from 33. 
 
1.2.3 Adenine Methylation in the Regulation of Virulence Factors 
Another task of 6mA is the regulation of virulence factors. Uropathogenic E. coli harbor a 
pyelonephritis-associated pili (pap)-operon, which encodes fimbrical adhesins that allow the 
pathogen to adhere to the urinary tract epithelium. Normally, the pap operon is switched off, 
based on distinctive methylation pattern in the pap regulatory region.42 This regulatory region 
contains two GATC sites (proximal and distal). In the off state, the Leucin responsive protein 
(Lrp) is bound at three downstream sites blocking RNA polymerase transcription. This binding 
of Lrp additionally reduces the affinity of Lrp-upstream binding, creating a feedback loop to 
keep the operon state switched off.43 While the Lrp protein binds to the downstream site, 
methylation of the proximal GATC is prevented. The distal GATC is free and becomes 
methylated. This off state is kept, until the PapI protein is present.42 Above a critical threshold, 
the switching factor PapI stimulates the Lrp translocation from downstream to upstream 
binding site. Distal GATC methylation is now prevented, while proximal GATC is methylated 
promoting the on state of the pap operon. A positive feedback loop sustains the on state and 
allows expression of fimbrical adhesins. Thus, the pathogen is able to invade the urinary 
bladder and cause urinary tract infection (see figure 5).33,42,44,45 
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Figure 5: Schematic display of the Pap operon. This regulatory domain comprises two GATC motifs which can 
exhibit a differential methylation status. This pattern allows the expression of fimbrical adhesins to promote the 
invasion and adhesion to the urinary mucosa and finally results in tract infection. 
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1.3 Adenine Methylation in Eukaryotic Genomes 
5mC and 6mA were discovered almost simultaneously a few decades ago. However, at that 
time research of 6mA was mainly focused on prokaryotic genomes. Due to the low abundance 
of 6mA in higher organisms and constraints in technological detection its potential epigenetic 
function has remained elusive until recently. With the use of highly sensitive modern mass 
spectrometry it became possible to detect trace amounts present in the cells, usually in the 
range of parts per million. This low occurrence, compared to 5mC, raised further doubts about 
the functional significance of 6mA in multicellular organisms and vertebrate tissue.46–48 
Nevertheless, a few early reports existed which accounted the presence of 6mA in eukaryotic 
DNA. Unicellular eukaryotes like ciliates and green algae were reported to contain both 6mA 
and 5mC in their genomes.49 However, the biological relevance of 6mA regarding involvement 
in epigenetic processes in higher organisms had remained vague. 
In May 2015 studies have shown the abundance of 6mA in three phylogenetically distinct 
eukaryotes Chlamydomonas reinhardtii50, Drosophila melanogaster51 and Caenorhabditis 
elegans52. First indications of potential epigenetic functions of 6mA in eukaryotic genomes 
were described along with new detection methods like UHPLC-MRM-MS/MS (ultra-high-
performance liquid chromatography-triple quadrupole mass spectrometry), 6mA targeted 
MeDIP-sequencing and other restriction assisted sequencing of DNA samples containing 
6mA.53 Parallel studies on claw frog (Xenopus laevis)54 and zebrafish (Danio rerio)55 attracted 
further attention to eukaryotic 6mA and spurred speculations how widespread this 
modification could be in vertebrates and mammalian genomes.36,56,57 Soon the occurrence of 
methylated adenine in mouse embryonic stem cells (mESC) was published58 and has been 
questioned59. Interestingly, the abundance of 6mA seemed to vary: Most tested organisms 
and tissues exhibited minute levels of 6mA (e.g. 0.00009 % 6mA/A in Xenopus), except for the 
green algae, which displayed the presence of 6mA in 84 % of all genes. In case of the fruit fly 
the levels of 6mA are dependent on the developmental stage of the organism. In the 
embryogenesis of Drosophila, the abundance of 6mA shows a 70-fold increase in initial stages 
compared to the adult stage (from 0.001 % to 0.07 % A/6mA). Comparable results were 
obtained in zebrafish and mice. The content of methylated adenine is doubled in the zebrafish 
zygote and increased further to a maximum of 0.1 % A/6mA in the 32/64 cell stadium. With 
the progressing development of the zebrafish, the abundance of 6mA dropped indicating a 
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role in the functional regulation of embryogenesis. While methylated adenine is evenly 
distributed in C. elegans, it is highly enriched in transcription starting sites in C. reinhardtii and 
in transposable elements of D. melanogaster implying not only a single role for eukaryotic 
6mA but also a species-specific function. 
Moreover, the studies revealed the existence of several 6mA-introducing and removing 
enzymes. In D. melanogaster, C. elegans and mESC 6mA-demethylases (and 
methyltransferase DAMT1 in the case of C. elegans) could be identified. In the fruit fly, the 
demethylase DMAD (diogxgenase Drosphila DNA 6mA demethylase) showed similar 
structural domains as the mammalian TET-enzyme. It was shown that this demethylase is 
specific for 6mA and does not demethylate 5mC, hmC or 6mA in RNA. Alterations in the 
expression of the demethylase lead to increased lethality of the Drosophila embryo. 
Comparable to these findings, deficiency of the identified mouse Alkbh1 demethylase caused 
reduction in litter size and resulted finally in embryonic lethality indicating a regulation 
mechanism for 6mA.  
Taken together these recent findings imply functional epigenetic roles of 6mA. In RNA, the 
profound effects of adenine methylation are extensively studied. In mammalian non-coding 
RNA and mRNA, 6mA can be catalyzed by demethylases generating intermediates like 
N6-hydroxymethyl adenine (6hmA) and N6-fomyl adenine (6fA). Since these recently 
discovered 6mA variants are stable modifications in RNA, they might possess regulatory 
functions.60 Furthermore, RNA carrying an adenine methyl group can be destabilized 
regarding Watson-Crick base-pairing to induce a switching mechanism that alters the RNA 
structure. Thus, binding of proteins to RNA can be influenced by the presence as well as the 
positioning of 6mA at the protein binding site. The same feature could be assigned to adenine 
N6-methyl groups present in DNA. It could affect gene transcription and inhibit or facilitate 
the binding of transcription factors or other DNA binding proteins.  
Since C. elegans and D. melanogaster have little or no 5mC in their genome, it is possible that 
the altering presence of this modification compared to other higher organisms, is the result 
of evolutionary events.56,57 Here, 6mA could play a predominant role in epigenetic processes 
and the identification of 6mA demethylases and methyltransferases implies that adenine 
methylation could be present in many more organisms. With the ongoing development and 
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continuous improvement of sensitive detection techniques, the function and precise 
distribution of eukaryotic 6mA could be explored throughout all domains of life (see figure 6). 
 
 
Figure 6: Overview of 6mA which was predominantly present in bacteria and archaea until recent findings. Three 
studies in phylogenetically distinct organisms reported the presence of 6mA in eukaryotic genomes. Further 
publications illuminated the abundance of 6mA in higher organisms like amphibia and mammalians. Image was 
adapted from 36. 
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1.4 Transcription-Activator-Like Effector Proteins 
Transcription-activator-like effectors (TALEs) are DNA binding proteins that are injected into 
plant cells by numerous phytopathogenic bacteria. After transfer to the host cell via the type 
III secretion system the TALE protein enters the nucleus and binds to effector specific 
promotors.61 Subsequently this will impair the host defense mechanisms or trigger a response 
beneficial for the bacterium. TAL effectors are key virulence factors for plant pathogens and 
can reprogram plant cells into mimicking eukaryotic transcription factors.62 TALEs have been 
found predominantly in species of Xanthomonas, but related homologs exist in Ralstonia 
solanacearum and Burkholderia rhizoxinica as well.63,64  
 
 
Figure 7: Crystal structure of the TALE protein PthXo1 binding to its target DNA from top view (left) and side 
view (right). The TALE (light blue) wraps itself along the major groove of the target DNA (blue) via concatenated 
repeats facilitating recognition and binding of the protein. Adapted from 65 and PDB entry 3UGM. 
 
The central DNA binding domain of TALEs consist of a unique structure which shows no 
similarity to known DNA binding proteins. In 2009, Boch and Bonas presented the setup of 
this central domain, along with the study of Moscou and Bogdanove which confirmed their 
findings by computational analysis.66,67 Soon after the first reports on TALEs its crystal 
structure (see figure 7) was elucidated.65 The high modularity enabled the development of 
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toolkits for customized TALE assembly. These are often based on Golden Gate cloning 
68,69,65,71, but also methods combining solid phase synthesis and standard cloning like fast 
ligation based automatable solid-phase high throughput (FLASH) exist. A detailed protocol on 
how the TALEs proteins are cloned in a Golden Gate (GG) approach is presented in section 
6.2. 
 
1.4.1 TALE Scaffold and Binding Mode 
TALE proteins are composed of three major parts: The N-terminal region (NTR), the central 
DNA binding domain and the C-terminal region (CTR). In Nature, the N-terminus of the protein 
contains the type III secretion signal which provides access to the host plant. The C-terminal 
region bears the nucleus localization sequence (NLS) as well as an activator domain. While 
the N-terminus binds the 5’-end of the target DNA, the C-terminal region faces the 3’-end. In 
between the N-and C-terminus the central repeat domain (CRD) is located. The CRD consists 
of tandem, concatenated repeats which each comprise 33 to 35 amino acids. These repeats 
are nearly identical and highly conserved except for the amino acid position 12 and 13. These 
positions are called repeat variable di-residues (RVD) and facilitate the TAL effector binding 
to the DNA sequence. TALEs recognize their target DNA via a simple one-to-one code (see 
figure 8): In nature, several RVDs are observed, however the most naturally occurring RVDs 
are HD, NG, NN and NI which respectively specify the DNA nucleobases C, T, G/A and A. Other 
less frequent RVDs like NS and N* exhibit lose specificity (the asterisk incorporates a missing 
amino acid at position 13 forming a 33 amino acid repeat).72,73 RVDs NH and NK are less 
common and show increased specificity for guanine (G). The central repeat domain is 
terminated with a truncated repeat containing the first 20 amino acids and is commonly 
referred to as half or last repeat (LR).66 
Each TALE repeat consists of two α-helices with the RVD residing in an interhelical loop 
domain. The residue at position 12 in each RVD is facing away from the DNA interacting with 
the proteins’ backbone carbonyl at position 8 thus stabilizing the interhelical loop. The residue 
at position 13 faces the DNA and looms deep into the major grove facilitating sequence-
specific contact with a single DNA nucleobase (see figure 8). It has been observed that most 
contacts between the RVD and DNA bases are resulting from direct hydrogen bonds (e.g. HD 
in contact with cytosine between the aspartate (D) carboxyl-group and 4-amino group of C), 
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highly steric packing (e.g. alpha carbon of glycine (G) of NG to extra cyclic methyl carbon of 
thymine base) or reduced specificity via steric exclusion of alternative DNA nucleobases (NI 
RVD).74 Moreover, studies revealed that HD and NN repeats procure a significant contribution 
to overall TALE binding affinity, while NI and N* repeats appear to result in reduced activity 
and lower specificity.73 Depending on the target sequence context selectivity effects have 
been reported.75,76  
 
 
Figure 8: Framework of TAL effector proteins. Each TALEs consists of multiple concatenated, conserved repeats 
which comprise 34 amino acids (left). Position 12 and 13 of each repeat are variable residues (RVD) and form a 
loop which is embedded into two α-helices (below). The RVDs of the TALE protein facilitate the contact and 
binding to the target DNA and follow a simple cipher in which the RVDS NI, NN, NG and HD specifically recognize 
A, G/A, T and C nucleobases (right). Adapted from 77. 
 
Besides the CRD, the N-terminus of TALE proteins also plays a key role when it comes to DNA 
binding. Crystallographic resolution of the N-terminus illuminated that this region is crucial 
for full activity of TALE proteins.78 Although the underlying mechanism is not yet well 
understood it was shown that the NTR comprises 4 continuous “cryptic” repeats analogous 
to the canonical repeats of the CRD. These additional N-terminal repeats follow the TALE 
taxonomy and are named repeat 0, -1, -2 and -3. The cryptic repeats provide the main part of 
binding energy. They exhibit positively charged patches evoked by arginine and lysine 
residues.78,79 These conserved residues contribute to the overall basic charge of the TAL 
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protein implying promoted nucleic acid binding by the NTR, however, this binding occurs to 
be non-specific and sequence independent of the target DNA .78,80,81 
Despite deciphering the TALE code and insights of the binding affinity of TALE proteins to 
DNA, little is known how the proteins search and recognize their target. Studies of other DNA 
binding proteins observed either a mechanical salt-dependent “hopping mechanism” in which 
the protein is involved in cycles of binding and unbinding to the DNA or a “sliding mechanism” 
whereas the protein slides along the DNA helix. TALE proteins have been described to be a 
hybrid of both.82 A model suggested that TALE proteins take a conformation wrapping itself 
loosely along the DNA helix during nonspecific search. Upon encountering a target site, TALEs 
compress and “verify” the local sequence thus resulting presumably in stable binding. 
  
23 
 
1.4.2 DNA Binding Proteins and TALE Applications 
In the past decade, several approaches have emerged which offer targeting and manipulation 
of any gene of interest from a wide range of different cell types and organisms. The discovery 
of programmable proteins like TALES, Clustered Regularly Interspaced Short Palindromic 
Repeats (CRISPR-CAS) and Zinc Fingers (ZF) equipped scientists with an unmatched ability to 
alter cells and organisms in their genomic setup. In the case of TALEs and ZFs the versatility 
of is based on the modularity of the DNA binding domain enabling recognition of any DNA 
sequence. Zinc Fingers consist of 30 amino acids and contain two conserved pairs of cysteines 
and histidines which are stabilized by one zinc ion. Each finger is built-upon an antiparallel β-
sheet recognizing 3 to 4 DNA nucleotides and inserting an α-helix structure into the major 
groove of the DNA. ZFs were the first programmable DNA binding proteins harnessing 
genome editing approaches. However, design and selection of each ZF turned out to be 
laborious and time consuming since neighboring ZFs influenced specificity and enhanced off 
target effects. The fortuitous discovery of TALEs offered an easier assembly approach. The 
TALE modules appeared to be mostly independent of neighboring influences and were 
publicly available, which allowed inexpensive and quick generation of custom TALEs. Only 3 
years after the TALE recognition mode was decoded, the CRISPR-CAS platform was developed. 
While TALEs and Zinc Fingers exhibit highly modular DNA binding domains, the CRISPR-CAS 
system relies on RNA-DNA recognition. The advantage of the CRISPR-CAS system is based on 
the easy RNA design and a single constant Cas9 nuclease. For DNA cleavage, the Cas9 is guided 
by an RNA (gRNA) which will hybridize to its target DNA sequence to facilitate binding of the 
CRISPR-CAS system. CRISPR-CAS has been shown to be effective in most established model 
organisms and cell cultures. However, it showed off target effects just like TALEs and Zinc 
Fingers. In all three protein models, most off-target and specificity problems have been 
overcome by simple adjustments e.g. truncation of the gRNA. The most exciting aspects of 
these DNA targeting proteins is how efficiently they have been used and how broad their 
effective application can be reported in many model organisms from crop plants and livestock 
to humans. For example, TALEs can be exploited for gene editing. Hereby the protein is fused 
to a nuclease domain (e.g. TALE with FokI domain) and introduces double strand breaks in 
vivo which are repaired by non-homologous end joining (NHEJ) or homologous recombination 
(HR). Thus, deletions, insertions or mutations can be established in the genome. Moreover, 
DNA binding proteins can be harnessed for tracking or imaging studies when connected to a 
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fluorescent domain like GFP (green fluorescent protein). Likewise, the fusion of the DNA 
binding protein to a transcriptional regulator facilitates expression or inhibition of the target 
gene. Besides alterations to the genome, the epigenome can also be manipulated. A study 
showed that site specific removal of cytosine methylation is possible by cloning TET catalytic 
domains to TALE proteins.83 Similarly, TALES linked to histone demethylase protein LSD1 
altered histone methylation and the introduction of methylation by fusing TALE proteins with 
methyltransferases has been reported to be successful.68–71 
 
1.4.3 TALEs and Epigenetics 
TALE proteins can also be used for targeted transcription regulation and altering the 
epigenetic setup. A critical property of TALEs is their central DNA binding domain. For any 
genome targeting approach high sequence selectivity is required. Consequently, to avoid any 
off target binding effects of TALEs, maximal RVD selectivity is needed and studies on 
mutational analysis have offered improved RVDs.87,88 Interestingly, another critical 
characteristic of TALEs is their sensitivity towards DNA nucleobases which carry epigenetic 
modifications. For instance, the RVD HD is shown to be sensitive to 5mC. If 5mC is present in 
the target sequence, TALE binding is abolished.89–91 5mC has been identified to be present in 
CpG islands embedded in many promotor regions. This critical regulatory element is generally 
chosen for knock out studies of genes with therapeutic and biotechnological interest. This 
negative impact on TALE binding has led to the development of customized RVDs which 
exhibit similar binding affinity to C and 5mC.89 It was suggested that the TALE repeat N* can 
efficiently accommodate methylated cytosine and thus overcome the methylation sensitivity 
of TALEs. However, this discriminatory binding affinity can also be exploited to develop TALE 
repeats binding to the full range of epigenetic modified nucleobases like 5hmC, 5fC and 
5caC.12,92–94 Moreover, binding affinities of TALES to other modified DNA like 6mA or 
N4-methyl cytosine (N4mC) bases are yet unknown. In the light of recent studies of 6mA being 
present in eukaryotic genomes in organisms from all domains of life, it is important to 
understand and investigate the specific binding capability of TALEs to this epigenetic 
nucleobase. 
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2. Aim of Work 
The specific detection of epigenetic marks might open the door for the diagnosis and 
subsequent treatment of numerous diseases which are based on a disorder of the DNA 
methylation pattern as known for the case of 5mC. In the past decade, lots of effort went into 
the development of protein-DNA recognition systems. The present work is located at the 
interface of DNA-protein interaction studies and the influence of epigenetic signals with the 
specific task to illuminate the binding behavior of TALEs to DNA harboring 6mA modifications. 
The first step is the interrogation of the RVD NI interacting with DNA representing naturally 
occurring methylation sites in uropathogenic E. coli (Pap operon). For further insights, the 
canonical NI will be mutated to RVDs facilitating a less polar surface and the resulting 
interaction with 6mA will be examined. Moreover, polar RVDs will be created which could 
enable H-bonding to the N6-amino group or N7-O-atom of adenine and thus exhibit 
differential TALE binding. DNA. A second approach is the expansion of the N6-methyl group 
with bulkier substituents in the form of SAM analogs, which can be transferred to the GATC 
motif by the Dam methyltransferase. Here, we interrogate the ability of TALEs to accept large 
groups facing the major groove of the DNA paving the way for smart TALE design and labeling 
strategies with bulky fluorophore labels. 
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3. Results and Discussion 
 
3.1 Selection of TALE Target-DNA 
For the interrogation of TALE binding affinity to epigenetically modified DNA a sequence 
context was chosen which is regulated via the reversible methylation of adenine. Two 
naturally occurring 17-nucleotide long sequences, namely Pap2 and Pap5 were chosen. Both 
hold a regulatory GATC site within the E. coli pap operon (see figure 9). Methylation of the 
N6-position of adenine within the proximal (Pap2) and distal (Pap5) GATC site occurs via the 
Dam methyltransferase. The methylation determines binding of the leucine-responsive 
regulatory protein and leads to the expression of pyelonephritis-associated pili (Pap). 
Ultimately this results in the adhesion of uropathogenic E. coli (UPEC) to the mucosa cells as 
a basic mechanism for many urinary tract infections.42,44,45,95  
 
   
 
Figure 9: Overview of selected target DNA sequence for TALE targeting. The GATC sites are underlined with A or 
6mA of interest in red. The sequences are 17 nucleotides (nt) long and the nucleobase of interest is located at 
position 7 of the oligos. Additional truncated oligos were designed for a later investigation sequence length 
dependency of TALE proteins. Adapted from 77. 
 
3.2 TALE Assembly and Expression 
The TALE proteins used in this work were generated based on the Xanthomonas axonopodis 
scaffold. A protocol for the respective golden gate assembly was established by the group of 
Daniel Voytas.96,97 Hereby, the constructed TALE proteins contain a truncated N-terminus 
(+136 amino acids from the first canonical repeat) which harbors a thioredoxin (TRX) or green 
fluorescent protein (GFP)-tag. In contrast to natural TALEs, the proteins assembled in the lab 
lack the translocation signal, the nuclear localization signal (NLS) and the activation domain 
27 
 
in the C-terminus. The TALE repeat arrays were assembled according to the sequences of Pap2 
and Pap5. After the first and second round of the Golden Gate reaction the E. coli BL21 cells 
were transformed with the generated plasmids for selection. The protein was isolated and 
purified via C-terminal His6 affinity tag by Ni-NTA chromatography. The purity and correct 
protein size was verified by SDS-PAGE analysis (see figure 10). For detailed description of TALE 
assembly and expression see methods 6.2.2 and 6.2.3. 
 
 
Figure 10: Exemplary image of 8 % SDS resolving gel containing expressed and purified TALE proteins with 
thioredoxin tag. From left to right: TALE_Pap2_NI, TALE_Pap2_NL and TALE_Pap2_NV (first and second elution). 
Constructed TALEs contain 17 repeats (including T0) and carry a mass of approx. 86.32 kDa. As a marker, the 
protein broad range maker from NEB was used (2-212 kDa, P7702S). Image is adapted from 77. 
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3.3 TALE-Binding to N6-Methyl Adenine 
3.3.1 Interrogation of the natural RVD NI binding to A and 6mA 
NI is the most frequently found natural occurring RVD in TALEs for binding of the nucleobase 
A.66,67,87,98 However, it is unknown how the NI TALE repeat interacts with an N6-methylated 
adenine. The steric changes introduced by the N6-methyl group might weaken or abolish the 
target affinity. It is well known that isoleucine at position 13 in the RVD NI (I13) generates a 
hydrophobic surface at the Hoogsteen face of A. Crystal structures report atomic distances 
between 3.8 and 4.1 angstrom between A and I13 (see figure 11).65,99  
 
 
Figure 11: Crystal Structure of the RVD NI to the nucleobase adenine (A). Dotted lines indicated the distances 
from position 12 and 13 in angstrom. Adapted from 77. 
 
Furthermore, a hydrophobic interaction between the N6-amino hydrogen of A and the O4 of 
a paired thymine nucleobase might move the N6-methyl group towards the side chain of I13. 
Therefore, an interaction of the TALE RVD NI with 6mA seems possible. To test this 
hypothesis, expressed TALEs (Pap2_NI) were employed in electromobility shift assays (EMSA) 
using a GFP fluorophore tag as a read out. TALEs targeting the Pap2 sequence were incubated 
together with unlabeled DNA oligonucleotide duplexes comprising either A or 6mA at position 
7 opposite the TALEs RVD NI. The result displayed the formation of defined TALE-DNA 
complexes with increased electromobility in comparison to sole TALE protein. Interestingly 
the results do not show differences in TALE binding to DNA containing either A or 6mA (see 
figure 12.  
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Figure 12: Interaction of TALE RVD NI with A and 6mA-containing DNA oligos carried out in EMSA assay. A: Amino 
acid sequence of expressed TALE_Pap2_NI targeting the Pap2 DNA sequence with the RVD NI in bold black. B: 
EMSA gel with TALE Pap2_NI in complex with various concentrations of DNA duplexes, free TALE protein in the 
right well shows lower electromobility than TALE-DNA complexes. C: Quantification of EMSA assay with a 
TALE/DNA ratio of 6.5:1 (n=3). Image was adapted from 77. 
 
It could be possible, that no discrimination of 6mA was observed due to a low nucleobase 
selectivity for the EMSA assay. In order to investigate the aforementioned results in further 
detail, a primer extension assay was carried out. The primer extension assay provides higher 
selectivity and sensitivity and therefore might unveil subtle differences in TALE binding to A 
or 6mA which are likely not to be seen in an EMSA assay (see figure 13 and methods 6.2.5).  
 
 
Figure 13: Principle of TALE controlled primer extension assay. The TALE is shown as carton with the RVD of 
interest (here NI) in red which is positioned opposite the nucleobase A or 6mA (red, imbedded in GATC site). 
Image was adapted from 77 
 
If the TALE protein is binding to its target sequence, the DNA polymerase is blocked and 
elongation of the primer template is inhibited. The 5’-32P labelled primer is hybridized to a 
template oligo containing the Pap2 target sequence and further incubated with 
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TALE_Pap2_NI protein. Eventually, dNTPs and Klenow Fragment were added to the mixture 
and further incubated. The reaction was resolved and monitored by denaturing 
polyacrylamide gel electrophoresis (PAGE) with 9 M urea. The extension product of the PAGE 
gel was quantified and employed as a measure of TALE binding (see figure 14).  
 
 
Figure 14: Primer extension assay with TALE_Pap2_NI binding to DNA oligo complexes. B: Image of urea PAGE 
gel with reactions containing 25 mU Klenow Fragment (exo-), 41.5 µM dNTP, 8.325 primer-template complex 
and various concentrations of TALE_Pap2_NI (541 nM, 333 nM, 166.5 nM and 8.32 nM) resulting in the displayed 
TALE/DNA ratios. B: Quantification of urea PAGE gel as a measure of TALE binding to A and 6mA (n=3). The image 
was adapted from 77. 
 
Despite greater sensitivity the primer extension assay also showed no differences in 
TALE_Pap2 binding. The same result was observed over varying TALE concentrations. 
Similarly, targeting the Pap5 sequence context yielded the same results. In order to exclude 
masking of potential selectivity caused by excessive binding energy, the experiments were 
repeated with truncated TALE_Pap2_NI variants. To achieve this, the truncated TALE versions 
were targeting only 16 or 15 nt Pap2 DNA duplexes. Again, no differences could be detected 
in the primer extension assay (see figure 15). A possible explanation is the probable 
accommodation and tolerance of 6mA by the RVD NI. Both experiments suggest additionally, 
that the N6-methyl group is barely involved in hydrophobic interactions with TALE. 
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Figure 15: Primer extension assay with truncated TALE_Pap2_NI binding to DNA oligo complexes with 17, 16 and 
15 nt. A: Quantification of the extension product as a measure of TALE binding in the primer extension assay 
(n=3). B: Pap2 sequence context with truncated versions used in this experiment. The nucleobase A or 6mA (red) 
is embedded in the GATC sequence. Adapted from 77. 
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3.3.2 Interrogation of Non-Polar RVDs Binding to A and 6mA 
Previous structural studies reported that adenine can be harbored by RVDs which carry a 
mutation in the amino acids at position 13. In the RVD NI the hydrophobic side chain directly 
faces the A nucleobase without favorable contact and may not exhibit a major contribution 
to the overall TALE affinity to DNA. Thus, NI was reported to be a weak RVD 73,99. However, it 
also indicates that isoleucine (see results 3.3.1) and another wide range of amino acids at 
position 13 could tolerate adenine and possibly N6-methyl adenine when there is no steric 
clash. Mutants with hydrophobic amino acids at position 13 seem to accommodate the 
adenine nucleobase but this remains still elusive.99 For further modulation of the hydrophobic 
surface of the RVD NI, the position 13 was replaced by a shorter valine (V) and a more flexible 
leucine (L). The generated RVDs NV and NL can provide deeper insights into the interaction 
of TALE proteins with 6mA. For testing the mutated RVDs, TALEs were generated that targets 
again the Pap2 sequence context. The RVDs were positioned opposite A or 6mA and primer 
extension experiments were carried out (TALE_Pap2_NL and TALE_Pap2_NV). In both cases, 
the TALE proteins exhibited similar binding to the DNA target compared to the wildtype RVD 
NI (see figure 16). 
 
 
Figure 16: Modulation of the hydrophobic surface of RVD NI. A: Principle of the TALE scaffold carrying the RVD 
NL, NV or NI at position 7, which is placed opposite A or 6mA. The mutations represent hydrophobic shorter (V) 
or more flexible (L) sidechains facing the nucleobase A or 6mA. B: Quantification of the primer extension assay 
as a measure of TALE binding carrying the RVDs NL and NV compared to wildtype NI (n=3). Adapted from 77. 
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This observation was also consistent for the Pap5 context (see figure 17). These findings imply 
that non-polar hydrophobic RVDs NL and NV accommodate A and 6mA without specific 
coordination and affinity. Furthermore, the N6-methyl group is tolerated and does not lead to 
a steric clash. This pronounced flexibility prevents hydrophobic interactions and is consistent 
with reported crystal structures 99. 
 
 
Figure 17: Quantification of the primer extension assay as a measure of TALE binding carrying the RVDs NL and 
NV compared to wildtype NI. Modulation of the hydrophobic surface of RVD NI. The mutations represent 
hydrophobic shorter (V) or more flexible (L) sidechains facing the nucleobase A or 6mA. Here the Pap5 sequence 
context was tested with TALE_Pap5 comprising either NI, NL or NV at repeat position 7. Adapted from 77 
 
To verify these data, models of TALE_Pap2_NI, TALE_Pap2_NV and TALE_Pap2_NL were 
conducted based on available crystal structures. All models were generated with DNA 
containing either A or 6mA at position 7 of the Pap2 operon. The model for the wildtype RVD 
NI displays the rotation of the terminal methyl group in the side chain of I13 to accommodate 
6mA. Similarly, a conformational change can be observed for L13. Both amino acid side chains 
prevent unfavorable interaction with the N6-methyl group via slight conformational changes. 
For the shorter side chain of V13 compared to I13 and L13, a larger distance to the nucleobase 
is revealed. Here, no rotation is observed for the accommodation of 6mA. All three models 
suggest that the N6-methyl group can be harbored in the RVD variants. The larger sidechains 
of NI and NL adapt and slightly rotate to conformations avoiding steric clash. The amino acids 
do not undergo hydrophobic interactions that lead to a measurable change in selectivity (see 
figure 18). 
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Figure 18: Superimposed models of TALE_Pap2 with mutated RVD containing I13, L13 or V13 (red). The TALE is 
shown as cartoon and binds to DNA carrying A or 6mA opposite the relevant RVD. Model containing A is 
displayed in gray, 6mA in light brown. A: The RVD wit Ile at position 13 interaction with A and 6mA. B: RVD NL 
interacting with A and 6mA. C: Model of RVD NV opposite of A or 6mA. Models were created in collaboration 
with Julia Jaspers and Oliver Koch, TU Dortmund. 
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3.3.3 Interrogation of Polar RVDs Binding to A and 6mA 
Previous studies have described that hydrophobic RVD mutants do not clash with adenine. 
This finding is consistent with the results of the present work. Models of RVD variants 
containing non-polar amino acids like proline, methionine and cysteine can accommodate the 
nucleobase adenine and therefore do not give rise to any steric constraints. Similarly, it has 
been reported that polar amino acids which do not form an H-bond to the opposite adenine 
adapt a conformation to avoid a steric clash.99 The naturally occurring RVD NN with polar 
asparagine (N13) is known to bind both, adenine and guanine. Crystal structures have 
unveiled that the side chain amide group of N13 forms an H-bond with the N7-atom of 
adenine.99 Yet, the binding affinity of NN with its polar surface to 6mA is unknown. Therefore, 
primer extensions with the RVD NN embedded in TALE_Pap2 were performed. The results 
exhibit similar binding to A and 6mA. The N6-methyl group shows little influence of the overall 
TALE binding affinity (see figure 19). Modelling of TALE_Pap2 with RVD NN indicate, that the 
N13 slightly rotates accommodating the methyl group of 6mA which results in a loss of the 
H-bond to the N7-amino group.  
 
 
Figure 19: Interaction of TALE_Pap2 containing the polar RVD NN wit A and 6mA. A: Quantification of primer 
extension. The TALE/DNA ratio was 60:1 (n=3). B: Superimposed modelling of TALE_Pap2_NN interacting with A 
(gray) or 6mA (light brown). Red dotted line indicates H-bonding. Models were created by Julia Jaspers and Oliver 
Koch, TU Dortmund. 
 
The next experiment was to examine the polar RVD NE. This RVD contains glutamic acid (E) at 
position 13 of the repeat. Reported in vivo activity assays with TALE nucleases utilizing NE 
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showed no binding to the nucleobase A.87,100 However, the models indicate that the side chain 
of E13 can reach further towards the major groove of the DNA and therefore direct H-bonding 
with the N6-methyl group can be observed in the crystal structure.99 These observations 
suggest that the binding of the RVD NE to 6mA could experience more influence by the N6-
methyl group. Surprisingly, the performed primer extensions did not indicate differences in 
binding of TALE_Pap2_NE to A or 6mA. Modelling of this interaction supports the hypothesis 
that the side chain of E13 reorients itself to accommodate the nucleobase. This results in a 
loss of the hydrogen bond to the adenine N6-methyl group. Furthermore, NE forms a 
hydrogen bond to its own backbone amide. This conformational change causes the precedent 
RVD to rearrange in order to avoid an unfavorable steric clash (see figure 20)  
 
 
Figure 20: Interaction of TALE_Pap2 containing the polar RVD NE wit A and 6mA. A: Quantification of primer 
extension. The TALE/DNA ratio was 60:1. B: Superimposed modelling of TALE_Pap2_NN interacting with A (gray) 
or 6mA (light brown). Models were created by Julia Jaspers and Oliver Koch, TU Dortmund. 
 
Taken together, the findings of non-polar RVDs (NI, NL and NV) as well as polar RVDs (NN, NE) 
do not exhibit differential binding to A or 6mA with the respective TALE protein. This indicates 
that the TALE repeat framework is not selective towards A and 6mA. The methylation 
insensitivity allows robust binding of the DNA by the TALE protein and enables user-defined 
binding to DNA loci which potentially contain epigenetically modified adenine. This makes it 
a useful tool for in vivo applications, where actual epigenetic modifications could occur 
depending on the target sequence. Consequently, testing TALEs with varied RVDs placed 
opposite other DNA nucleobases like thymine, cytidine and guanine did not result in 
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differential binding. These data indicate that TALE repeats have a high intrinsic motility to 
undergo conformational changes while accommodating A and 6mA while remaining a robust 
DNA binder. 
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3.4 Interrogation of TALEs to Bulky N6-Alkynyl Substituents 
The tolerance of TALEs harboring methyl groups at the N6-position of adenine raised the 
question if the protein can accommodate even larger substituents at this position. The 
recognition and binding mode of TALE proteins is directed towards the DNA major groove. 
This feature makes TALE proteins a useful capture tool for analytical approaches. For example, 
TALEs sensitive to methylation of cytosine can be used as selective fishing tools for DNA 
containing epigenetic bases like 5mC and 5hmC, thus delivering information about the 
presence and status of modified cytosine embedded in DNA samples based on TALE binding 
or abolished binding.12,32,92,93,101,102 All these applications would profit of fluorescently labeled 
DNA for detection. However, the optimal site to attach DNA labels is the 5-position of cytosine 
and thymine directed towards the DNA major groove. This site is recognized by methylation 
sensitive TALEs and could abolish binding. Thus, the N6-position could be an ideal site to 
introduce DNA labels which are tolerated during TALE binding. This blind spot could enable 
effective binding of TALE proteins to methylated and fluorophore-labeled DNA. Therefore, it 
was intriguing to investigate the introduction of larger substituents at this position. 
For the introduction of a label at the adenine position, S-adenosyl methionine (SAM) analogs 
were used. In nature, SAM is a common cosubstrate for enzymes which are involved in the 
transfer of methyl groups. In this process SAM is hydrolyzed to S-adenosyl homocysteine 
(SAH) and adenine. In bacteria, the Dam methyltransferase utilizes SAM to transfer a 
CH3-group to the N6-position of adenine. For the approach of interrogating larger 
substituents, the Dam enzyme represents a practical tool to introduce labels in the form of 
SAM analogs at adenine. The SAM analogs contain alkynyl-substituents which replace the 
electrophilic methyl group at the sulfonium center and therefore enlarge the moiety of the 
replaced methyl group. The SAM analogs were synthesized and then tested for acceptance 
by the Dam enzyme. In this assay, SAM-free Dam enzyme is needed to ensure a high yield of 
transferred groups and to avoid preference of the common SAM cofactor. The obtained 
results indicate that the synthesized SAM analogs are accepted by the Dam enzyme and that 
the substituents were successfully transferred to the A position within the GATC motif. The 
synthesis of the SAM variants, as well as the testing of the Dam tolerance was conducted in 
collaboration with the group of Elmar Weinhold, RWTH Aachen (see figure 21). 
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Figure 21: Modification of adenine at the N6-position embedded in the GATC motif of the pap operon (Pap2). 
The E. coli Dam enzyme transfers a methyl group from the SAM substrate to adenine (2a). In the reaction 
homocysteine (SAH) is produced. Other SAM analogs (1b and 1c) are accepted by the Dam transferase and can 
be transferred to the N6-position of adenine (2b and 2c). The SAM analogs as well as the expression of SAM-free 
Dam enzyme were provided by the group of Elmar Weinhold, RWTH Aachen. 
 
In our approach, we interrogated if labeled DNA would interfere with TALE binding. The SAM 
analog 1b was of special interest. This alkynyl substituent exhibits a certain flexibility and does 
not hold a branched structure. Another advantage is, that 1b can be used for posterior 
labeling. Via the Cu(I)-catalyzed [3+2] azide-alkyne cycloaddition further labels and 
fluorophores can be introduced. To test our hypothesis, DNA duplexes with the sequence 
context of the pap operon 2 were modified by the Dam enzyme with SAM and other 
synthesized SAM analogs (see also methods 6.2.4). After the transfer of the group of interest 
(1a, b or c) to the N6-position of adenine, the DNA was purified and subjected to mass 
spectrometry. The analysis by electrospray ionization time-of-flight (ESI-TOF) indicated 
quantitative labeling of both DNA strands with the substituent (see also appendix 7-11). Yet, 
the primer extension assay performed with labeled DNA (2b) and TALE_Pap2_NI protein did 
not exhibit differential binding of TALE protein (see figure 22). The TALE does not discriminate 
between DNA containing adenine or the 2b-labeled nucleobase. This result suggests that the 
larger alkynyl substituent is tolerated and well accommodated by TALEs even when the label 
is present in both DNA strands (see appendix 11). Models of this scenario indicate that the 
substituent can arrange and thread facing the open half of the groove towards the surface of 
the TALE-DNA complex. Furthermore, the model exhibits the possibility that even larger 
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substituents could be accommodated by TALEs when connected via the terminal alkyne 
moiety of 1b.  
 
 
Figure 22: Binding of TALE_Pap2_NI to larger substituents. A: Analysis of DNA oligonucleotides by ESI-TOF. The 
first spectrum shows the Pap2 DNA without labeling followed by labeling reaction resulting in 2a and 2b (from 
left to right), s = sense strand, a = antisense strand. Masses: s calc: 14977.8, s found: 14977.9; a calc: 15162.8, a 
found: 15163.9; 2b: s calc: 15082.8, s found: 15083; a calc: 15267.8, a found: 15268; 2c: s calc: 15713.1, s found: 
15714; a calc: 15898.1, a found: 15898.7. B: Quantification and analysis of TALE_Pap2_NI binding to DNA with 
or without substituents 2b and 2c. The TALE-DNA ratio was 60:1 (n=3). C: Superimposed models of 
TALE_Pap2_NI interacting with DNA either containing two adenines or 2a in each strand. The substituent 2a is 
positioned opposite the RVD NI in the sense strand (green sticks) as well as in the antisense strand embedded 
in the palindromic GATC motif (yellow sticks). D: Same superimposed model as in C but with differently 
orientated surface presentation. See also appendix 8 and 9. 
 
Based on the information of the modeling that the TALEs could accept even larger groups, the 
labeling reaction was repeated with the bulkier cofactor 1c. This cofactor is derived from the 
molecule 1b and extended by a tetramethylrhodamin (TAMRA) fluorophore via the Cu(I)-
catalyzed [3+2] azide-alkyne cycloaddition (see figure 21/1c). Analysis by ESI-TOF reported a 
successful labeling reaction but with reduced yield compared to 1b (see appendix 11). 
Nonetheless, primer extension again did not show any distinction in TALE_Pap2_NI binding 
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to either DNA containing A or 2c nucleobase. This finding implies that the bulky TAMRA group 
of 2c is exposed to the surface of the complex and that the N6 position is a blind spot for larger 
substituents. The N6-adenine position holds the possibility for even larger fluorophore labels 
to be tolerated by TALE proteins (see figure 23). 
 
 
Figure 23: Model of TALE-Pap2_NI binding to DNA comprising substituents of the N6-adenine position. The TALE 
protein is targeting DNA towards the major groove. Substitution of the N6-methyl group by bulkier substituents 
still allows accommodation by the RVD NI. Even larger groups as a dialkynyl substituent and expanded 
fluorophore dye like TAMRA can be accepted by TALEs at this site. The bulky substituents are exposed to the 
surface of the TALE-DNA complex. Image from 77. 
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4. Summary and Outlook 
TALE proteins are DNA binding proteins and useful tools for genome targeting and 
engineering approaches. TALEs represent convenient, programmable tools to target DNA for 
in vivo and in vitro applications. These proteins exhibit a high flexibility which is based on their 
framework of modular repeats. TALEs consist of multiple concatenated repeats which are 
highly conserved but harbor a variable part (RVD). Each RVD enables the selective recognition 
of one DNA nucleobase and stabilizes the interaction between DNA target and TALE protein. 
Each TALE can be assembled in the lab which makes the proteins versatile, effective targeting 
tools. However, knowledge is required about their binding behavior to DNA, especially if the 
target sequence comprises epigenetically modified nucleobases. Earlier studies reported 
methylation sensitive TALEs of 5-methyl cytosine and many approaches were developed to 
overcome this sensibility or to utilize it as effective sensory tools.12,32,89,93 However, apart from 
epigenetic 5-methyl cytosine and its higher oxidized derivatives, the binding ability of TALE 
proteins to DNA containing the epigenetic mark of N6-methyl adenine (6mA) was unknown. 
To shed light on this, we examined the binding of TALEs to the 6mA. This epigenetic mark is 
predominantly found in prokaryotic genomes but was recently reported to be present in 
eukaryotic organisms. In this work, we find that the naturally occurring RVD NI, which 
recognizes the DNA nucleobase A, is not sensitive towards 6mA. Model-assisted studies with 
RVD variants generating more hydrophobic surfaces and the disposition for hydrogen bonding 
to the N6-amino group or N7-atom of adenine showed that 6mA is well accommodated by the 
RVD mutants. Based on the modelling results, it was suggested that even larger groups at the 
N6-position could be tolerated. Therefore, we used bulky N6-alkynyl-substituents which can 
be transferred to the GATC motif by the Dam enzyme. These substituents can be utilized and 
extended for even larger groups like rhodamine dyes by simple click chemistry reaction. And 
indeed, TALEs can also accommodate bulky N6-substitutions. Taken together, we report the 
first TALE binding studies to the epigenetic base of 6mA and its bulky substituents. Unlike 
cytosine and 5mC, 6mA is well tolerated by natural and modified RVDs and therefore, 6mA 
likely does not interfere in TALE based targeting approaches. In conclusion, these findings 
report the N6-position of adenine as a blind spot for TALE proteins which allows the 
introduction of labels without interferences. These results allow valuable insights for 
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prospective approaches using TALEs and expand their scope of application as capture probes 
with labeled DNA. 
As complementary approach, the identification of further RVD variants, which could recognize 
6mA, could deliver further insights into the TALE DNA interaction. Libraries containing RVDs 
with mutations of the amino acid alphabet at position 13 might identify 6mA methylation 
sensitive TALE RVDs.102 Also, structure-function studies on the repeat loop could deliver 
further information about TALEs interacting with N6-substituents and other potential DNA 
fluorophores.92 Consequently, these finding could be expanded to other DNA contexts, which 
hold for example the epigenetic mark N4-methyl cytosine, which like 6mA, is predominantly 
found in prokaryotic genomes. Furthermore, crystal structures of TALES interacting with 
epigenetically modified DNA could support recent findings. With these approaches, further 
insights to TALEs interacting with epigenetic bases could be illuminated and used as useful 
knowledge for TALE construction, smart design of fluorescently labeled DNA as well as 
targeting and engineering approaches. 
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5. Zusammenfassung und Ausblick 
TALE Proteine sind DNA bindende Proteine und sind ein nützliches Werkzeug für biologische 
Anwendungen, wie zum Beispiel die gezielte Einführung von Modifikationen im Genom einer 
Zelle. TALEs stellen ein günstiges, programmierbares Instrument dar, mit welchem DNA-
Sequenzen in Experimenten genau angesteuert werden können. Diese Anwendung ist für in 
vivo und in vitro Versuchen möglich. TALE Proteine besitzen eine sehr hohe Flexibilität, welche 
auf einem Gerüst von sogenannten Repeat-Modulen basiert. Diese Proteine bestehen aus 
mehreren miteinander verketteten Repeats, welche hoch konserviert sind, jedoch einen 
variablen Bereich besitzen (RVD). Jeder dieser variablen Bereiche ermöglicht die selektive 
Erkennung von DNA Nukleinbasen und stabilisiert zusätzlich die Interaktion zwischen DNA 
und TALE Protein. Der modulare Aufbau der TALEs erlaubt die einfache Assemblierung dieser 
Proteine im Labor womit zahlreiche und vielfältige Anwendungen durchgeführt werden 
können. Jedoch setzt dies Wissen über das Bindeverhalten der TALE Proteine zur DNA voraus, 
insbesondere wenn die Zielsequenz epigenetische Modifizierungen beinhalten könnte. 
Frühere Studien berichten über 5-Methyl-Cytosin-sensitive TALEs und es wurden zahlreiche 
Ansätze entwickelt diese Sensitivität zu umgehen oder sie als sensorisches Werkzeug zu 
nutzen.12,32,89,93 Jedoch ist bisher nicht bekannt, abgesehen von 5-Methyl-Cytosin (5mC) und 
seinen oxidierten Derivaten, wie TALE Proteine and DNA bindet, die die epigenetische Base 
N6-Methyl-Adenosin (6mA) in seiner Sequenz trägt. Um dies zu beleuchten, untersuchten wir 
die Bindung von TALEs mit 6mA. Dieses epigenetische Signal kommt hauptsächlich in 
prokaryotischen Genomen vor, jedoch wurde es kürzlich auch in eukaryotischen Organismen 
nachgewiesen.51,54–56,103. In dieser Arbeit wird berichtet, dass das natürlich vorkommende 
RVD NI, welches die Nukleinbase Adenosin erkennt, nicht sensitiv gegenüber 6mA ist. Model-
basierte Studien mit verschiedenen RVD Varianten, welche eine hydrophobere Oberfläche 
oder H-Brückenbildung zur N6-Gruppe oder dem N7-Atom ermöglichen könnten, zeigten, dass 
6mA von den RVDs durch kleinere konformative Änderungen innerhalb des TALE Proteins 
akzeptiert werden kann. Es erschien möglich, dass sogar größere Gruppen an der N6-Position 
durch die RVDs beherbergt werden könnte. Daher wurden in weiteren Experimenten größere 
N6-Alkynyl-Substituenten an die entsprechende Position angebracht. Ein Vorteil dieser 
Substituenten ist, dass diese von der Dam Methyltransferase akzeptiert werden und auf das 
GATC Sequenzmotiv übertragen werden können. Diese Substituenten können durch Click-
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Chemie mit zusätzlichen Gruppen, wie beispielsweise Rhodamin Farbstoffen, erweitert 
werden. Tatsächlich binden TALE Proteine auch an DNA, welche diese größeren N6-Gruppen 
trägt. Im Gegensatz zu 5mC, kann 6mA von natürlichen und modifizierten RVDs beherbergt 
werden und zeigt vermutlich keinen Einfluss auf die TALE Bindung zur DNA. Diese Ergebnisse 
zeigen, dass die N6-Position als ein blinder Punkt für TALE Proteine sein könnte, welcher die 
Einführung von Labeln ohne Einflussnahme auf die Protein-DNA Bindung erlaubt. Diese 
Ergebnisse erlauben wertvolle Einblicke für weitere TALE Anwendungen und erweitern den 
Einsatzumfang von TALE Proteinen mit markierter DNA. 
Komplementäre Ansätze zur Identifizierung von 6mA-sensitiven RVD Varianten könnten die 
Einblicke in die TALE-DNA Interaktion vertiefen. Die Generierung von RVD-Bibliotheken, 
welche Mutationen des gesamten Aminosäuren-Alphabetes and Position 13 tragen, könnte 
6mA-bindende RVD Varianten zu Tage befördern.102 Des Weiteren könnten weitere Struktur-
Funktions-Studien über die Repeat-Schleife weitere Informationen über TALEs, die mit 
größeren N6-Gruppen und potentiellen Fluorophoren interagieren, liefern.92 Diese Ergebnisse 
könnten auf andere DNA-Sequenzkontexte erweitert werden, welche beispielsweise die 
epigenetische Modifikation N4-Methyl-Cytosin beinhalten, die wie 6mA überwiegend in 
prokaryotischen Genomen vorkommt. Außerdem könnte die Erzeugung von 
Kristallstrukturen von TALEs in Interaktion mit epigenetischen Basen bisherige Ergebnisse 
unterstützen und möglicherweise weitere Einblicke liefern. Diese Ergebnisse und Ansätze 
können verwendet werden für die Generierung von TALE Proteinen, sowie das smarte Design 
von Fluorophor-markierter DNA. 
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6. Materials and Methods 
6.1 Materials 
6.1.1 Oligonucleotides 
DNA oligonucleotides were purchased from Sigma-Aldrich (0.025 μmol scale, purified by 
desalting) or from Metabion for methylated oligos (A). Oligonucleotides were stocked as 100 
μM solutions in water. Working concentration of primers were adjusted to 10 μM.  
 
Table 1: List of oligonucleotides used for primer extension assay. 
 
Lab Code Name/Locus Sequence (5'-3') 
oSaB_899 Lrp_Pap5 TTC TGC GAA AAG AAA GTC CGT AAA AAT TCA TTT AGA CGA TCT 
TTT ATG C 
oSaB_873 Lrp_Pap5 TTC TGC GAA AAG AAA GTC CGT AAA AAT TCA TTT AGA CGA TCT 
TTT ATG C 
oSaB_770 Lrp_Pap5 GCA TAA AAG ATC GTC TA 
oSaB_900 Lrp_Pap2 GTT TTG TTC TAG TTT AAT TTT GTT TTG TGG GTT AAA AGA TCG 
TTT AAA T 
oSaB_874 Lrp_Pap2 GTT TTG TTC TAG TTT AAT TTT GTT TTG TGG GTT AAA AGA TCG 
TTT AAA T 
oSaB_875 Lrp_Pap2 ATT TAA ACG ATC TTT TA 
 
Table 2: List of oligonucleotides used for electromobility shift assay. 
 
Lab Code Name/Locus Sequence (5'-3') 
oSaB_900 Lrp_Pap2 GTT TTG TTC TAG TTT AAT TTT GTT TTG TGG GTT AAA AGA TCG 
TTT AAA T 
oSaB_874 Lrp_Pap2 GTT TTG TTC TAG TTT AAT TTT GTT TTG TGG GTT AAA AGA TCG 
TTT AAA T 
oSaB_1815 Lrp_Pap2 ATT TAA ACG ATC TTT TAA CCC ACA AAA CAA AAT TAA ACT AGA 
ACA AAA C 
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Table 3: List of oligonucleotides used for site directed mutagenesis. 
 
Lab Code Name/Locus Sequence (5'-3') 
oSaB_808 pNI6_I13L_fw TCG CCA GCA ACC TGG GCG GCA AGC AAG CGC T 
oSaB_809 pNI6_I13L_rv GCT TGC TTG CCG CCC AGG TTG CTG GCG ATA GC 
oSaF_1110 pNI6_I13V_fw CTA TCG CCA GCA ACG TTG GCG GCA AGC AAG CGC TCG 
oSaF_1111 pNI6_I13V_rv GCG CTT GCT TGC CGC CAA CGT TGC TGG CGA TAG CCA C 
oSaF_1315 pNI6_I13E_fw GTG GTG GCT ATC GCC AGC AAC GAA GGC GGC AAG CAA 
oSaF_1316 pNI6_I13E_rv CGC TTG CTT GCC GCC TTC GTT GCT GGC GAT AGC CAC 
 
Table 4: List of oligonucleotides used for sequencing 
 
Lab Code Name/Locus Sequence (5'-3') 
oSaB_247 Seq. Primer GGG TTA TGC TAG TTA TTG CTC AG 
oDaS_315 Seq. Primer CGT AGA GGA TCG AGA TC 
oSaB_734 Seq. Primer TTG ATG CCT GGC AGT TCC CT 
oSaB_735 Seq. Primer CGA ACC GAA CAG GCT TAT GT 
oSaB_814 Seq. Primer AAT GCG CAA ACC AAC CC 
oSaB_890 Seq. Primer AGA TAT GAT TGC GGC CCT G 
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6.1.2 Plasmids 
 
Table 5: List of plasmids via TALE assembly and site directed mutagenesis. 
 
Lab Code Name/Locus   
pSaB327 pNI6_I13V Tet QC pNI6 Module 
pSaB328 pNI6_I13L Tet QC pNI6 Module 
pSaB339 pET-TRX-FINAL_FINAL_ENTRY Carb Backbone Vector 
pSaB340 pap_lrp5_16 in pSaB339 Carb TALE plasmid 
pVaS342 pap_lrp2_16 in pSaB339 Carb TALE plasmid 
pVaS343 pap_lrp2_15 in pSaB339 Carb TALE plasmid 
pVaS344 pap_lrp2_14 in pSaB339 Carb TALE plasmid 
pVaS345 pap_lrp5_15 in pSaB339 Carb TALE plasmid 
pVaS360 pap_lrp2_16.NV6 in pSaB339 Carb TALE plasmid 
pVaS361 pap_lrp2_16.NL6 in pSaB339 Carb TALE plasmid 
pSaF469 pap_lrp5_16 NL in pSaB339 Carb TALE plasmid 
pSaF470 pap_lrp5_16 NV in pSaB339 Carb TALE plasmid 
pAnI521 pET_GFP_FINAL_ENTRY Carb Backbone Vector 
pSaF522 pHD6_D13E Tet QC pHD6 Module 
pSaF523 pNI6_I13E Tet QC pNI6 Module 
pMoS715 pET_araBAD-GFP_FINAL_ENTRY Carb Backbone Vector 
pSaF1105 pap_lrp2_16_NN6 in pSaB339_TRX  Carb TALE plasmid 
pSaF1106 pap_lrp2_16_NE6 in pSaB339_TRX  Carb TALE plasmid 
pSaF1107 pap_lrp2_16_NI in pAnI521_GFP  Carb TALE plasmid 
pSaF1108 pap_lrp2_16_NL in pAnI521_GFP  Carb TALE plasmid 
pSaF1109 pap_lrp2_16_NV in pAnI521_GFP  Carb TALE plasmid 
pSaF1110 pap_lrp2_16_NN in pAnI521_GFP  Carb TALE plasmid 
pSaF1111 pap_lrp2_16_NE in pAnI521_GFP  Carb TALE plasmid 
pSaF1112 pap_lrp5_16_NI in pAnI521_GFP  Carb TALE plasmid 
pSaF1113 pap_lrp5_16_NL in pAnI521_GFP  Carb TALE plasmid 
pSaF1114 pap_lrp5_16_NV in pAnI521_GFP  Carb TALE plasmid 
pSaF1115 pap_lrp5_16_NN in pAnI521_GFP  Carb TALE plasmid 
pSaF1116 pap_lrp5_16_NE in pAnI521_GFP  Carb TALE plasmid 
pSaF1117 pap_lrp2_16_NI in pMoS715_GFP  Carb TALE plasmid 
pSaF1118 pap_lrp2_16_NV in pMoS715_GFP  Carb TALE plasmid 
pSaF1119 pap_lrp2_16_NN in pMoS715_GFP  Carb TALE plasmid 
pSaF1120 pap_lrp2_16_NE in pMoS715_GFP  Carb TALE plasmid 
pSaF1121 pap_lrp5_16_NI in pMoS715_GFP  Carb TALE plasmid 
pSaF1122 pap_lrp5_16_NL in pMoS715_GFP  Carb TALE plasmid 
pSaF1123 pap_lrp5_16_NV in pMoS715_GFP  Carb TALE plasmid 
pSaF1124 pacyc_trcPromotor_Lrp2_16_GATC_mplum Cam Target plasmid 
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6.1.3 TALE Proteins 
 
Table 6: Overview of expressed TALE proteins. 
 
Lab Code Name/Locus Plasmid 
TALE_026 Lrp_Pap5_16_NI_TRX pSaB340 
TALE_027 Lrp_Pap2_16_NI_TRX pVaS342 
TALE_029 Lrp_Pap2_15_NI_TRX pVaS343 
TALE_030 Lrp_Pap2_14_NI_TRX pVaS344 
TALE_031 Lrp_Pap5_15_NI_TRX pVaS345 
TALE_032 Lrp_Pap5_14_NI_TRX pVaS346 
TALE_033 Lrp_Pap2_16_NV_TRX pVaS360 
TALE_034 Lrp_Pap2_16_NL_TRX pVaS361 
TALE_035 Lrp_Pap5_16_NV_TRX pSaF470 
TALE_036 Lrp_Pap2_16_NL_TRX pSaF469 
TALE_112 Lrp_Pap2_16_NN_TRX pSaF1105 
TALE_113 Lrp_Pap2_16_NE_TRX pSaF1106 
TALE_316 pap_lrp2_16_NI_GFP pSaF1107 
TALE_317 pap_lrp2_16_NL_GFP pSaF1108 
TALE_318 pap_lrp2_16_NV_GFP pSaF1109 
TALE_319 pap_lrp2_16_NN_GFP pSaF1110 
TALE_320 pap_lrp2_16_NE_GFP pSaF1111 
TALE_321 pap_lrp5_16_NI_GFP pSaF1112 
TALE_322 pap_lrp5_16_NL_GFP pSaF1113 
TALE_323 pap_lrp5_16_NV_GFP pSaF1114 
TALE_324 pap_lrp5_16_NN_GFP pSaF1115 
TALE_325 pap_lrp5_16_NE_GFP pSaF1116 
TALE_326 pap_lrp2_16_NI_araBAD_GFP pSaF1117 
TALE_327 pap_lrp2_16_NV_araBAD_GFP  pSaF1118 
TALE_328 pap_lrp2_16_NN_araBAD_GFP pSaF1119 
TALE_329 pap_lrp2_16_NE_araBAD_GFP pSaF1120 
TALE_330 pap_lrp5_16_NI_araBAD_GFP pSaF1121 
TALE_331 pap_lrp5_16_NL_araBAD_GFP pSaF1122 
TALE_332 pap_lrp5_16_NV_araBAD_GFP pSaF1123 
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6.1.4 Bacterial Strains 
 
Table 7: Overview of bacterial strains used for cloning and expression of TALE proteins. 
 
Lab Code E. coli Strain Genotype Supplier 
BL21 DE3 sMoS308 fhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS λ DE3 = λ sBamHIo ΔEcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 Δnin5  Stratagene 
BL21 DE3 Gold sMoS309 F- ompT gal dcm lon hsdS (rB– mB– ) λ(DE3 [laci lacUV5-T7 gene 1 ind1 sam7 nin5)  Agilent 
GH371 sDaS58 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 ΔlacX74 
recA1 araD139 Δ(araleu)7697 galU galK rpsL (StrR) endA1 
nupG fhuA::IS2 upp-  
iGEM 
K12 ER 2925(Dam-) sSaF374 
ara-14 leuB6 fhuA31 lacY1 tsx78 glnV44 galK2 galT22 mcrA 
dcm-6 hisG4 rfbD1 R(zgb210::Tn10)TetS endA1 rpsL136 
dam13::Tn9 xylA-5 mtl-1 thi-1 mcrB1 hsdR2 
New Englang Biolabs 
K12 ER 2738(Dam+) sSaF375 F´proA
+B+ lacIq Δ(lacZ)M15 zzf::Tn10(TetR)/ fhuA2 glnV 
Δ(lac-proAB) thi-1 Δ(hsdS-mcrB)5 
AG Goettrup, Konstanz 
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6.1.5 Media 
 
Table. 8: Overview of media used for optimal growth of E. coli. 
 
Type of Media Chemical Concentration 
LB-medium (Lysogeny Broth) 
(pH = 7.0) 
Tryptone 
Yeast extract 
NaCl 
10 g/L 
5 g/L 
5 g /L 
LB-agar 
(pH = 7.0) 
Tryptone 
Yeast extract 
NaCl 
Agar-Agar 
10 g/L 
5 g/L 
5 g/L 
15 g/L 
SOC-medium 
(pH = 7.0) 
Tryptone  
Yeast extract  
NaCl  
KCl  
MgCl2  
MgSO4  
Glucose  
2 % (w/v)  
0.5 % (w/v)  
10 mM  
2.5 mM  
10 mM  
10 mM  
20 mM  
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6.1.6 Buffers 
 
6.1.6.1 Buffers for Protein Purification 
 
Table 9: Buffers for native purification of TALE proteins with GFP-tag. 
 
Native purification Chemicals Concentration 
Qiagen lysis buffer  
(pH = 8.0) 
NaH2PO4  
NaCl  
50 mM  
300 mM  
Qiagen wash buffer 1 
20 mM Imidazole 
(pH = 8.0) 
NaH2PO4  
NaCl  
Imidazole  
50 mM  
300 mM  
20 mM  
Qiagen wash buffer 2 
50 mM Imidazole 
(pH = 8.0) 
NaH2PO4  
NaCl  
Imidazole  
50 mM  
300 mM  
50 mM  
Qiagen elution buffer 
500 mM Imidazole  
(pH = 8.0) 
NaH2PO4  
NaCl  
Imidazole  
50 mM  
300 mM  
500 mM  
PBS (4x)  
(pH = 8.0) 
NaCl  
KCl  
Na2HPO4  
KH2PO4  
548 mM 
43 mM 
69 mM 
24 mM  
 
Table 10: Buffers for denaturing workup of TALE proteins with TRX-tag. 
 
Native purification Chemicals Concentration 
Taq lysis buffer  
(pH = 9.0) 
Tris*HCl 
NaCl 
MgCl2 
TritonX-100  
100 mM  
300 mM  
2.5 mM 
0.1 % (v/v) 
Buffer-Z wash buffer 1 
(pH = 8.0) 
Urea  
NaCl  
Hepes  
Imidazole  
8 M  
100 mM  
20 mM  
20 mM  
Buffer-Z wash buffer 2  
(pH = 8.0) 
Urea  
NaCl  
Hepes  
Imidazole  
8 M  
100 mM  
20 mM  
50 mM  
Buffer-Z elution buffer  
(pH = 8.0)  
Urea  
NaCl  
Hepes  
Imidazole  
8 M  
100 mM  
20 mM  
500 mM  
PBS (4 x)  
(pH = 8.0) 
NaCl  
KCl  
Na2HPO4  
KH2PO4  
548 mM 
43 mM 
69 mM 
24 mM  
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6.1.6.2 Buffer for Dialysis of TALE Proteins 
 
Table 11: Overview of used dialysis buffers. 
 
Dialysis buffer Chemicals Concentration 
5 x TALE storage buffer 
(pH = 7.5) 
Tris*HCl 
NaCl 
Glycerol  
100 mM 
1 mM 
50 % (v/v) 
 
6.1.6.3 Reaction Buffers 
 
Table 12: Reaction buffers for Primer Extension. 
 
Primer Extension Chemicals Concentration 
5 x TALE storage buffer 
(pH = 7.5) 
Tris*HCl 
NaCl 
Glycerol 
100 mM 
1 mM 
 50 % (v/v) 
5 x TALE binding buffer Tris*HCl (pH = 8) 
NaCl 
MgCl2 
BSA 
Glycerol  
100 mM 
250 mM 
25 mM 
0.5 mg/ml 
50 % (v/v) 
KF storage buffer Tris*HCL (pH = 7.5) 
EDTA 
DTT 
Glycerol  
25 mM 
0.1 mM 
1 mM 
50 % (v/v) 
 
 
Table 13: Reaction buffers for EMSA. 
 
EMSA Chemicals Concentration 
5 x BGrK1 
(pH = 7.5) 
Tris*HCl (pH = 8) 
NaCl 
MgCl2 
100 mM 
250 mM 
25 mM 
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Table 14: Reaction buffers for alkylation by Dam methyltransferase. 
 
Alkylation  Chemicals Concentration 
Dam reaction buffer (10 x) 
(pH = 8) 
Tris*HCl (pH = 8) 
EDTA 
DTT 
1500 mM 
100 mM 
20 mM 
Dam storage buffer  
(pH = 7.5) 
Tris*HCl 
KCl 
EDTA 
DTT 
Glycerol 
50 mM 
50 mM 
10 mM 
1 mM 
52.5 % (v/v) 
 
6.1.6.4 Buffers for Gel-Electrophoresis 
 
Table 15: Buffers and gel composition for denaturing PAGE. 
 
Denaturing PAGE Chemicals Concentration 
TBE running buffer (10 x) Tris*HCl 
Boric Acid 
EDTA 
890 mM 
890 mM 
20 mM 
TBE running buffer/Urea Tris*HCl 
Urea 
Boric Acid 
EDTA 
890 mM 
9 M 
890 mM 
20 mM 
Denaturing PAGE gel  
(10 %) 
Sequencing gel concentrate  
10 x TB / 9 M urea  
9 M urea  
APS (10 % w/v) 
TEMED  
40 ml  
10 ml  
50 ml  
800 μl  
40 μl  
Denaturing loading buffer Formamide 
EDTA 
Bromophenol blue 
80 % (v/v) 
2 mM 
1 g 
 
Table 16: Buffers and gel composition for EMSA. 
 
EMSA Chemicals Concentration 
10 x TAE Tris*HCl 
Boric Acid 
EDTA 
890 mM 
890 mM 
20 mM 
EMSA native gel Gel 40 concentrate  
10 x TAE buffer 
MilliQ-H2O 
APS (10 % w/v) 
TEMED 
2 ml 
0.5 ml 
7.4 ml 
100 µl 
10 µl 
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Table 17: Buffers for Agarose Gel-Electrophoresis. 
 
Agarose Electrophoresis Chemicals Concentration 
TBE running buffer (0.5 x) Tris*HCl 
Boric Acid 
EDTA 
45 mM 
45 mM 
1 mM 
NEB gel loading dye (6 x) FicollR-400 
EDTA 
Tris*HCl 
SDS 
Bromophenol blue 
15 % (v/v) 
66 mM 
19.8 mM 
0.102 % (w/v) 
0.09 % (w/v) 
Staining solution Ethidium bromide 0.1 % (w/v) 
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Table 18: Buffers and gel composition for SDS-PAGE. 
 
SDS-PAGE Chemicals Concentration 
SDS loading buffer (4 x)  
pH = 6.8  
Tris*HCl  
Glycerol  
2-Mercaptoethanol  
SDS  
Bromophenol blue  
200 mM  
40 % (v/v)  
1 % (v/v)  
8 % (w/v)  
0.008 % (w/v)  
SDS running buffer (10 x)  Tris Base  
Glycerol  
SDS  
30.3 g/L  
144 g/L  
10 g/L  
Resolving gel (8 %)  MilliQ-H2O  
Gel 40 (40 % Acrylamid-, Bisacrylamid 37,5:1)  
Tris (1.5 M, pH = 8.8)  
SDS (10 % w/v)  
APS (10 % w/v)  
TEMED  
3808 μl  
1092 μl  
420 μl  
66.7 μl  
66.7 μl  
6.67 μl  
Stacking gel (5 %)  MilliQ-H2O  
Gel 40 (40 % Acrylamid-, Bisacrylamid 37,5:1)  
Tris (0.5 M, pH = 6.8)  
SDS (10 % w/v)  
APS (10 % w/v)  
TEMED 
1000 μl  
208 μl  
420 μl  
16.7 μl  
16.7 µl 
1.67 µl 
Coomassie staining  MilliQ-H2O  
Acetic Acid  
Methanol  
Coomassie Brilliant Blue G250  
40 % (v/v)  
10 % (v/v)  
50 % (v/v  
0.1 % (w/v)  
Coomassie destaining  MilliQ-H2O  
Acetic Acid  
Methanol  
70 % (v/v)  
10 % (v/v)  
20 % (v/v)  
 
6.1.6.5 Buffers for Chemically Competent Cells. 
 
Table 19: Buffers for preparation of chemically competent E. coli cells. 
 
Buffer Chemicals Concentration 
MgCl2-buffer MgCl2 100 mM 
CaCl2-buffers CaCl2 50 mM 
Storage-buffer CaCal2 
Glycerol  
50 mM 
15 % (v/v) 
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6.1.7 Antibiotic Stocks, Enzymes and Kits. 
 
Table 20: Overview of antibiotic stocks. All antibiotics were dissolved in their respective solvent and were 
subsequently sterile filtered with a 0.2 µM syringe filter. 
 
Antibiotic Stock Solvent Concentration 
Chloramphenicol (Cam) Ethanol 34 mg/L 
Carbenicillin (Carb) Ethanol/MilliQ-H2O-H2O (1:1 v/v) 50 mg/L 
Spectinomycin (Spec) MilliQ-H2O 100 mg/L 
Tetracycline (Tet) Ethanol 12.5 mg/L 
 
Table 21. Overview of enzymes used for various reactions. 
 
Enzymes Commercial Supplier 
BsaI  New England Biolabs 
BsmBI  New England Biolabs 
Dam mtase (S-adenosylmethionine free) AG Weinhold, Aachen 
DpnI  New England Biolabs 
DpnII New England Biolabs 
KF(exo-)  New England Biolabs 
Lysozyme  Fluka  
Plasmid safe nuclease Biozym  
Phusion polymerase  New England Biolabs 
Taq polymerase NEB/self-expressed  
T4-DNA ligase  New England Biolabs 
T4 polynucleotidekinase  Fermentas  
T5 exonuclease New England Biolabs 
 
Table 22: Kits. 
 
Kits CommercialSupplier 
BCA Protein Assay Thermo Scientific 
BCA Protein Assay (DTT compatible) Thermo Scientific 
GeneJET Gel Extraction Kit Thermo Scientific 
GeneJET Plasmid Miniprep Kit Thermo Scientific 
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6.1.8 Reagents and Chemicals 
 
Table 23: Used reagents and chemicals in this work. 
 
Reagents and Chemicals Commercial Supplier 
Acetic acid Carl Roth 
Agar-Agar (Cobe I) Carl Roth 
Agarose Biozym 
Ammonium persulfate (APS) Carl Roth 
Boric Acid Carl Roth 
Bovine Serum Albumin (BSA) Cell Signaling 
Bromphenol blue Carl Roth 
Calcium Chloride Fisher Scientific 
Carbenicillin disodium salt Carl Roth 
Chloramphenicol Carl Roth 
Coomassie Brilliant Blue G250 Carl Roth 
Disodiumhydrogen phosphate Sigma Aldrich 
dNTPs New England Biolabs 
Dithiothreitol (DTT) Carl Roth 
Ethanol p.a. Sigma Aldrich 
Ethanol 96% Fisher Scientific 
Ethidium bromide Sigma Aldrich 
Ethylenediaminetetraacetate (EDTA) Carl Roth 
Formamide Acros 
[gamma-32P]-ATP Hartmann Analytics 
Glucose Carl Roth 
Glycerol Carl Roth 
Hepes Carl Roth 
Hydrochloric Acid (37%) VWR 
Imidazole Abcr 
Isopropanol (99.9%) Fisher Scientifc 
Isopropyl ß-D-1thiogalactopyranoside (IPTG) Carl Roth 
Kanamycinsulfate Carl Roth 
L-Arabinose Carl Roh 
LB-agar Carl Roth 
LB-medium Carl Roth 
LE-agarose Carl Roth 
Magnesium chloride hexaydrate Acros 
Magnesium sulfate heptahydate Merck 
Methanol Sigma Aldrich 
Nickel Nitrilotriacetic acid (Ni-NTA resin) Thermo Scientific 
Phenylmethanesulfonyl fluoride (PMSF) Carl Roth 
Potassium chloride Carl Roth 
Potassium dihydrogenphosphate monohydrate (KH2PO4) Sigma Aldrich 
Protein Marker Broad Range (2-212 kDa) New England Biolabs 
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Rotiphorese Gel 40 Carl Roth 
Rotiphorese sequencing gel concentrate Carl Roth 
S-adenosylmethonine New England Biolabs 
Sodium chloride (NaCl) Carl Roth 
Sodium dihydrogen phosphate monohydrate Merck 
Sodium dodecyl sulfate (SDS) Carl Roth 
Sodium hydroxide (NaOH) Fisher Scientific 
Spectinomycin Alfa Aeser 
Tetracyclin hydrochlorid Carl Roth 
Tetramethylethyldiamine (TEMED) Carl Roth 
Tris(hydroxymethyl)-aminomethan (TRIS) Sigma Aldrich 
Tryptone Carl Roth 
Triton X-100 Fluka 
Unstained protein marker 2-212 kDa New England Biolabs 
Urea Carl Roth 
Xylene cyanole Carl Roth 
Yeast extract Carl Roth 
2-Log DNA ladder New England Biolabs 
2-Mercaptoethanol Merck 
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6.1.9 Lab Equipment 
 
Table 24: Used lab equipment for this work. 
 
Lab Equipment Commercial Supplier 
Autoclave Systec 
Balance ABT 220-4M  Kern  
Balance PlJ 3500-2NM  Kern  
Balance SE622  VWR  
Biophotometer Plus  Eppendorf  
Centrifuge 5810R  Eppendorf  
Centrifuge Universal 320R  Hettich  
Centrifuge Sorvall Evolution RC Thermo Scientific 
Concentrator plus speed-vac Eppendorf 
Contamat FHT 111M Thermo Scientific 
Electrophoresis power supply EV233  Consort  
Electrophoresis power supply EV243  Consort  
Electrophoresis power supply EV245 Consort 
Electrophoresis power supply  BioRad 
Fridge ProLine (4°C) Liebherr  
Freezer ProLine (-20°C) Liebherr 
SDS-PAGE Gel electrophoresis system BioRad  
Gel electrophoresis system Midicell Primo EC330 Thermo Scientific 
Gel electrophoresis system 45-2010-i Peqlab 
Gel documentation BDA digital  Biometra  
Gel Dryer MGD 4534  VWR  
Homogenizer Emulsi-Flex-C5 Avestin 
Heating block digital dry bath  Labnet 
Ice machine AF20 Scotsman 
Incubator  Memmert 
Incubator INCU-line  VWR  
Infinite M200 plate reader  Tecan  
Incubator 1000  Heidolph  
Magnetic stirrer MR Hei-standard  Heidolph  
Magnetic stirrer MR3002  Heidolph  
Magnetic stirrer RCT Classic  IKA  
Microwave MW82N  Samsung  
Millipore filter system ELGA 
Multichannel pipette 10 μl (8 channels) Research Plus  Eppendorf  
Multichannel pipette Xplorer 100 μl (12 channels)  Eppendorf  
PCR Cycler (Mycycler)  BioRad  
PCR Cycler (Primus 25 advanced)  Peqlab  
pH Meter  Mettler Toledo  
Phosphor screen cassettes BAS 2025  Fuji  
Phosphor imager Molecular Imager Chemi-Doc  BioRad  
61 
 
Pipette boy Easypet  Eppendorf  
Pipettes Research Plus Eppendorf 
Phosphor imager Pharos-FX Plus BioRad 
Phosphorimager Typhoon FLA 9500 GE Healtcare 
Research Plus Pipettes (2.5, 10, 100, 1000 μl)  Eppendorf  
Sequencing Gel System BioRad 
Sequencing Gel System Carl Roth 
Shaking Incubator Ecotron  Infors HAT  
Shaking Incubator I26 New Brunswick Scientific 
Shaker Unimax 1010 Heidolph 
Sonicator Digital Branson 
Tabletop Centrifuge 5417R  Eppendorf  
Tabletop Centrifuge 5424  Eppendorf  
Tabletop Centrifuge Minispin Carl Roth 
Thermomixer comfort  Eppendorf  
Thermomixer compact  Eppendorf  
Thermomixer 96 well plate BioER 
Thermomixer 96 well plate MB-102 BioER 
Ultra-low temperature freezer (-80°C) New Brunswick Scientific 
UV-Star UV-table (312 nm)  Biometra  
Vacuum pump Vaccubrand 
Vortex Genie 2 Scientific Industries  
Water bath JB Aqua 12 Plus  Grant  
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6.1.10 Consumables 
 
Table 25: Single-use products consumed in this work. 
 
Consumables Commercial Supplier 
96-deep well plates  Sarstedt  
96-well plates transparent  Carl Roth  
96-well plates, flat bottom  Greiner  
Amicon Ultra MWCO 3 kDa  Millipore  
Cannulas Sterican 0.60 x 80 mm  Braun  
Cannulas Sterican 0.80 x 120 mm  Braun  
Cannulas Sterican 0.90 x 40 mm  Braun  
Colum (PP 5ml) Qiagen 
Cuvettes semi-mikro  VWR  
Falcon tube 15 ml  Sarstedt  
Falcon tube 30 ml  Sarstedt  
Glas beads  Carl Roth  
Gloves Nitrile  VWR  
PCR tubes 0.2 ml  Sarstedt  
Petri dishes Sarstedt  
Pipette tips  Sarstedt  
Reaction tubes 1.5 ml  Sarstedt  
Reaction tubes 2 ml  Sarstedt  
Scalpel  Mediwar  
Self adhesive cover film Ratiolab 
Sephadex columns G25  Life Technologies  
Serological pipette 10 ml / 25 ml  Sarstedt  
Slide-A-Lyzer Mini Dialysis Unit MWCO: 10 kDa  Thermo Scientific  
Syringe  Henke Sass Wolf  
Syringe needle  Braun 
Syringe filter 0.2 μM  Sarstedt  
UV-transparent disposable cuvettes  Sarstedt  
Whatman paper 3 mm  Whatman  
ZelluTrans dialysis membrane visking Cellulose Carl Roth  
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6.1.11 Software 
 
Table 26: Software used for documentation, analysis, quantification and presentation of results. 
 
Software Supplier 
BioDoc Analyse Geldokumentation Analytic Jena 
ChemDraw Professional 15 Cambridgesoft 
CorrelDraw Graphic Suite X6 Softronic 
FinchTV Geospiza 
ImageJ 1.50i Nat. Institute of Health 
MS Office Microsoft 
Serial Cloner Serial Basics 
Pymol DeLanoScientific LLC 
Quantity One BioRad 
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6.2 Methods 
6.2.1 General Biomolecular Methods 
6.2.1.1 Preparation of Chemically Competent Cells 
20 ml of LB-media was inoculated with a single E. coli colony picked from an agar plate. The 
culture was incubated at 37°C overnight shaking at 180 rpm. The next day, 800 ml of LB-
medium was inoculated with 8 ml of the overnight culture. The culture was incubated at 37°C 
until the OD600 nm of 0.4 was reached. The culture was cooled on ice and equally distributed 
to 16 flacon tubes (50 ml). Cells were harvested by centrifugation at 4000 rpm at 4°C for 10 
min. The supernatant was discarded and the pellet were resuspended in 10 ml MgCl2 buffer. 
The cell suspension was centrifuged again and the remaining pellets were resuspended in 10 
ml CaCl2 buffer. The bacterial suspension was incubated for 30 min on ice and again 
centrifuged at 4°C, 4000 rpm for 10 min. The supernatant was discarded and the pellets were 
pooled and resuspended in an overall volume of 4 ml storage buffer. The cell suspension was 
aliquoted and snap frozen with liquid nitrogen. The cells were stored at -80°C. 
 
6.2.1.2 Transformation of Chemically Competent Cells 
About 10 to 100 ng of plasmid solution was mixed with 50 µl of chemically competent E. coli 
cells (50 µl aliquot). The suspension was mixed carefully by stirring with a pipette tip and 
incubated on ice for 30 min. Then, the cells were heat shocked at 42°C for 30 seconds, 
incubated again on ice for 2 min. The cells were rescued with 1 ml pre-warmed SOC by 
incubation at 37°C for 1 h (1000 rpm shaking). After incubation, the cells were plated on LB-
agar plated supplied with the respective antibiotic and incubated at 37°C overnight. 
 
6.2.1.3 Isolation of Plasmids  
For isolation of plasmids, 5 ml of LB-media was inoculated with a single colony picked from 
an agar plated. The culture was supplied with the respective antibiotic and incubated at 37°C 
overnight. The next day, the culture was pelleted by centrifugation at 4000 rpm for 10 min 
and the supernatant was discarded. The pellet was resuspended in 250 µl of resuspension 
buffer and transferred to a 1.5 Eppendorf tube following the manufacturers protocol (GenJET 
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plasmid Minprep Kit, Qiagen). Then, 250 µl lysis solution were added and the rubes were 
inverted several times followed by addition of neutralization buffer and repeated inversion. 
After centrifugation for 5 min at 1400 rpm the supernatant was isolated from the cell debris 
and transferred to the supplied columns. After centrifugation for 1 min, 500 ml of washing 
buffer was added and the flow through was discarded. The columns were centrifuged for 1 
min to remove remaining washing buffer. Finally, the columns were placed in a new 1.5 ml 
Eppendorf tube and air dried to remove residual ethanol. 50 µl of MilliQ-H2O were added to 
the column and the plasmids were eluted by centrifugation at 14000 rpm for 2 min. 
 
6.2.1.4 Sanger Sequencing of DNA  
5 µl of 30-75 ng of DNA, 2.5 µl of respective primers (2.5 µM) and 2.5 µl of MilliQ-H2O were 
mixed and send for sequencing in a 1.5 ml Eppendorf tube to GATC biotech company. 
Sequence traces were analyzed using Finch TV software and aligned to theoretical sequences 
using Serial Cloner software. 
 
6.2.1.5 Agarose Gel-Electrophoresis 
Agarose powder was resuspended in 0.5 x TBE buffer and heated in a microwave until it was 
completely dissolved. The solution was cooled to approximately 40°C and then poured into a 
gel casting tray. A comb was placed on top and the polymerized gel was transferred to a gel 
chamber filled with 0.5 x TBE buffer. Prepared DNA samples were mixed with DNA loading 
dye and carefully loaded onto the gel. The gel was run for 1 h at 120 V or adjusted conditions 
for higher resolution. The gel was incubated in an aqueous ethidium bromide solution for 5 
min and destained in MilliQ-H2O. The gel was put on a Biometra UV-table (254 nm) and the 
image was collected by a gel documentation system. If necessary, DNA fragments could be 
extracted from the agarose gel by excising the fragment from the gel with a scalpel followed 
by use of GenJET gel extraction kit (Qiagen). 
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6.2.2 Cloning and Modification of Plasmids 
6.2.2.1 Site Directed Mutagenesis 
For introduction of site-directed mutagenesis of TALE module plasmids (repeat position 13) 
primers were designed following the guidelines from Agilent for QuikChange site directed 
mutagenesis. Forward and reverse primers exhibit melting temperatures of ≥ 78°C, a GC 
content above 40 % and the ends should possibly contain a G or C. The lengths of the primers 
varied to match the required melting temperatures, but were commonly between 30 to 45 
bp. The desired mutational site should be placed in the middle part of the sequence with 15 
to 20 bp flanking it. 
The reaction was performed in a total volume of 25 µl. The reaction mix contained 10 to 50 
ng template plasmid, 200 µM dNTPs, 200 nM forward and reverse primers, as well as Pfu Ultra 
DNA polymerase and its respective reaction buffer. The reaction was carried out with an initial 
denaturation step for 30 s at 95°C, followed by 16 cycles of 30 s at 95°C, annealing for 60 s at 
55°C and elongation at 60 s per kb at 68°C. The final elongation was conducted at 68°C for 7 
min followed by storage of the reaction at 4°C. Subsequently, the reaction was digested with 
DpnI (0.5 µl, 10 U) at 37°C for 1 h. Without further purification, 4 µl were transformed into 50 
µl of chemically competent E. coli GH371 cells. Clones were isolated and checked for correct 
mutagenesis by Sanger sequencing. 
 
6.2.2.2 TALE Assembly 
TALE plasmids were assembled according to a two-step Golden Gate protocol published by 
Cermark et al in 201197. The module repeat plasmids were assembled according to the desired 
RVD sequence using the module plasmids numbered in that order. The first intermediate 
array called pFUS_A can include up to 10 repeat modules. The next repeat modules are cloned 
into a second array pFUS_B (see figure 24). In the first Golden Gate reaction, the single 
module plasmids as well as the backbone intermediate arrays are subjected to digestion by 
BsaI enzyme at 37°C for 5 min followed by ligation with T4 DNA ligase at 16°C for 10 min. The 
reaction is incubated for 10 to 15 cycles, then heated to 50°C for 5 min and terminated at 
80°C for 5 min. 0.5 µl of ATP (25 mM stock) and 0.5 µl of plasmid safe nuclease are added to 
the 25 µl reaction and incubated at 37°C for 1 h. Eventually, the reaction was heat inactivated 
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by incubation at 70°C for 20 min. Approximately 4 µl of this reaction mix was transformed 
into E. coli GH371 cells without any further purification steps. Positive clones could be pre-
selected by a blue-white screening if XGal (5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside) was added to the plates. Up to 4 white clones were picked for further 
analysis by colony PCR. Therefore, 1 µl of the respective bacterial suspension was diluted to 
a 25 µl reaction volume supplemented with 250 µM dNTPs, 100 nM of forward and reverse 
primes oSaB374/oSaB375, 40 mU Taq polymerase and thermo pol buffer. The reaction mix 
was incubated at 94°C for 2 min, followed by 35 cycles of 94°C, 55°C 30 s, 68°C 2 min and a 
final extension step at 68°C for 2 min. The results of the colony PCR were monitored on a 1 % 
agarose gel for correct size. If the clones were identified with the correct size, 5 ml of 
overnight cultures supplied with spectinomycin were inoculated with the respective bacterial 
suspension. 1 µl of each bacterial suspension was spotted to a safe plate.  
 
 
Figure 24: First step of Golden Gate assembly of TALE protein. The module plasmids are arranged according to 
the sequence of interest and assembled to an array plasmid via a restriction and ligation reaction. Adapted from 
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The next day, plasmids were isolated and subjected to Golden Gate 2 reaction. In this 
reaction, the intermediate arrays pFUS_A and pFUS_B, along with the last repeat and the 
backbone vector pET_TRX_ENTRY or pET_GFP_ENTRY are joined (see figure 25). A 10 µl 
digestion with BsmbI restriction enzyme and ligation reaction mixture is prepared as in the 
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first step (10 cycles). Plasmid safe treatment was omitted in this step. About 4 µl of the 
reaction was transformed into expression strain E. coli BL21 (DE3). The transformed cells were 
plated on LB-agar plates supplemented with carbenicillin. The next day 4 white colonies were 
picked and monitored by colony PCR (primers oSaB890/oDaS247). If the size was correct, 5 
ml of LB-media cultures were inoculated with the respective bacterial suspension and 
incubated at 37°C overnight. The next day the plasmids were isolated and sent for sanger 
sequencing to check for correct sequence using sequencing primers oDaS315, oSaB890 and 
oDaS247. 
 
 
Figure 25: Second step of Golden Gate assembly of TALE protein. Each array plasmid can hold up to 10 repeat 
modules. Consequently, the array repeats and the last repeat are joined in a second restriction and ligation 
reaction and connected to the backbone vector, which holds the N-terminal and C-terminal domains of the 
protein. Adapted from 97. 
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6.2.3 Expression and Purification  
6.2.3.1 Expression and Purification of TALE Proteins with TRX-Tag 
Single clones of E. coli BL21 (DE3) Gold transformed with TALE expression plasmids 
(pSaB339_pET_TRX_final_entry) picked and 5 ml LB-media supplemented with 50 μg/ml 
carbenicillin was inoculated. The culture was incubated at 37°C overnight. The next day, the 
overnight cultures were diluted 40-fold into LB-medium supplemented with carbenicillin. The 
culture was grown at 37°C and 250 rpm shaking until an OD600 nm of 0.4 was reached and 
induced with a final concentration of 0.2 mM IPTG. After 5 h of incubation, expression culture 
was harvested by centrifugation (15 min, 4000 rpm, 4°C). The supernatant was discarded and 
the remaining pellet was lysed in Taq lysis-buffer supplied with 1 mM PMSF and 50 μg/ml 
lysozyme by shaking at room temperature at 1400 rpm for 30 min. The suspension was 
pelleted by centrifugation (20 min, 9000 rpm, 4°C) and the supernatant was discarded. Under 
denaturing conditions, the TALE protein was extracted from the pellet and bound to Ni-NTA 
resin according to the manufactures protocol. The resin was washed two times with 4 x PBS-
buffer four times with washing buffer 1 containing 20 mM imidazole and once with washing 
buffer 2 with 50 mM imidazole. Finally, the protein was eluted from the column with elution 
buffer containing 500 mM imidazole. The respective fractions were pooled and monitored by 
SDS-PAGE. 
 
6.2.3.2 Expression and Purification of TALE Proteins with GFP-Tag 
Single clones of E. coli BL21 (DE3) Gold transformed with TALE expression plasmids based on 
pET_GFP_final_entry (pAnI521) and expressed as described above. After 5 h of expression the 
cultures were harvested by centrifugation (15 min, 4000 rpm, 4°C). The remaining pellets 
were lysed in Qiagen lysis buffer containing 1 mM PMSF and 50 μg/ml lysozyme and 
additionally disrupted using French press. Then, the solution was centrifuged (15 min, 9.000 
rpm, 4°C), the supernatant was collected and extracted with Ni-NTA). For purification, the 
same procedure was applied as described for TRX-TALEs above. 
 
6.2.3.3 SDS-PAGE 
TALE proteins were monitored on 8 % SDS-PAGE gels. Proteins were analyzed on 8 % SDS-gels 
by PAGE. The resolving gel was prepared from 3808 μl MilliQ-water, 1092 μl Acrylamide 
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concentrate (40 %), 420 μl Tris (pH = 8.8), 66.7 μl SDS solution (10 %), 66.7 μl APS solution (10 
%) and 6.67 μl TEMED. After 30 min of polymerization, the stacking gel prepared from 1000 
μl MilliQ-water, 208 μl Acrylamide concentrate, 420 μl Tris (pH = 6.8), 16.7 μl SDS solution, 
16.7 μl APS solution and 1.67 μl TEMED was poured onto the resolving gel. Protein samples 
were mixed with 10 µl of SDS-PAGE loading buffer and denatured at 95°C for 5 min. 
Subsequently, 15 µl of the samples were loaded onto the gel. The gel was run at 120 V for 1.5 
h. Finally, after staining the gel with brilliant blue solution for about 30 to 60 min, the gel was 
destained and the image of the gel was documented. 
 
6.2.3.4 Dialysis and Storage of TALE Proteins 
The TALE proteins were placed into dialysis tubes (molecular weight cut off 10 kDa) and 
dialyzed against 1 x TALE storage buffer at 4°C. The buffer was changed several times until 
the concentration of imidazole from the elution buffer was diluted to a picomolar range. The 
purity of the TALE proteins was controlled by SDS-PAGE. Quantification of the protein 
concentration was performed with BCA assay (Thermo Fisher, compatible with DTT reducing 
agent) followed by snap freezing of 20 μl aliquots and long-term storage at -80°C. 
 
6.2.4 Enzymatic Alkylation of DNA Duplexes by Dam Methyltransferase 
Oligonucleotide pairs oSaB900/oSaF1815 and oSaB874/oSaF1815 were hybridized in 15.5 μl 
Dam reaction buffer by incubation mix at 95°C for 5 min. The hybridization was then allowed 
to room temperature for 30 min. SAM analogues were added (80 μM final concentration) and 
the pH was adjusted to 8.0 if necessary. After addition of 0.5 μl E. coli Dam enzyme (51.5 μM 
stock, 1.65 μg/ml) the reaction was incubated at 37 °C for 4 h in a final reaction volume of 
312.5 μl. The reaction mix was then purified with a PCR cleanup kit (Qiagen) and the amount 
of DNA was quantified by UV absorption measurement. The reaction was checked for correct 
alkylation by sending samples to Metabion international AG to perform ESI-TOF mass 
spectrometry. 
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6.2.5 Primer Extension 
Oligonucleotides o875 and o770 were 32P-radiolabeled at the 5’-end using [gamma]-32P-ATP 
and T4 polynucleotide kinase. The labeled oligos were purified by G-25 gel filtration. The 
template oligonucleotides and radiolabeled primers (oSaB900/oSaB874, oSaB899/oSaB873) 
were diluted to 6 µl of hybridization buffer and incubated at 95°C for 5 min. The hybridization 
mix (was then allowed to cool to room temperature for 30 min. 6 µl of varying concentrations 
of TALE protein diluted in 1 x TALE storage buffer were added to the hybridization mix and 
incubated for another 30 min at room temperature. 12 µl of Klenow Fragment E. coli DNA 
polymerase (30 mU, 3'-5' exo-) were added to the reaction resulting in a final concentration 
of 8.325 nM and 25 nM for primer and template, respectively. The reaction was incubated for 
15 min, then stopped with addition of 12 µl of PAGE loading buffer and incubation at 95°C for 
5 min. The samples were loaded onto a pre-run denaturing PAGE gel (9 M urea) and it was 
run in 1 x TBE buffer at 120 W for 1 h. Then, the gel was transferred to Whatman paper and 
covered with cling film. The gels were dried for a minimum of 1 h and a phosphor plate was 
exposed to it overnight. The next the image of the gel was collected by a phosphor imager 
and analyzed by ImageJ/Quantity One software. 
 
6.2.6 Electromobility Shift Assay 
Oligonucleotide pairs oSaB900/oSaF1815 and oSaB874/oSaF1815 were incubated at 95°C for 
5 min in 1 x BGrK1 buffer. After hybridization of the oligos, the samples were cooled to room 
temperature for 30 min. 1.5 pmol of TALE protein with N-terminal GFP domain was incubated 
with varying concentrations of DNA (2.5 pmol – 0.5 pmol) at room temperature for 30 min 
and additional 30 min on ice. The reaction was carried out in 1 x BGrK1 buffer resulting in a 
final volume of 10 μL. 5 μl of the reaction mix were loaded onto a pre-run EMSA gel and run 
with 70 V for 90 min at 4 °C. The GFP-fluorescence of the TALE-proteins was recorded with a 
Typhoon FLA-9500 laser scanner and TALE-DNA complexes were analyzed with ImageJ 
software. 
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8. Appendix 
 
ATGAGCGATAAAATTATTCACCTGACTGACGACAGTTTTGACACGGATGTACTCAAAGCGGACGGGGCGATCCTCGTCGATTT
CTGGGCAGAGTGGTGCGGTCCGTGCAAAATGATCGCCCCGATTCTGGATGAAATCGCTGACGAATATCAGGGCAAACTGACCG
TTGCAAAACTGAACATCGATCAAAACCCTGGCACTGCGCCGAAATATGGCATCCGTGGTATCCCGACTCTGCTGCTGTTCAAA
AACGGTGAAGTGGCGGCAACCAAAGTGGGTGCACTGTCTAAAGGTCAGTTGAAAGAGTTCCTCGACGCTAACCTGGCCGGTTC
TGGTTCTGGCGAACGCCAGCACATGGACAGCCCAGATCTGGGTACCGTGGACTTGAGGACACTCGGTTATTCGCAACAGCAAC
AGGAGAAAATCAAGCCTAAGGTCAGGAGCACCGTCGCGCAACACCACGAGGCGCTTGTGGGGCATGGCTTCACTCATGCGCAT
ATTGTCGCGCTTTCACAGCACCCTGCGGCGCTTGGGACGGTGGCTGTCAAATACCAAGATATGATTGCGGCCCTGCCCGAAGC
CACGCACGAGGCAATTGTAGGGGTCGGTAAACAGTGGTCGGGAGCGCGAGCACTTGAGGCGCTGCTGACTGTGGCGGGTGAGC
TTAGGGGGCCTCCGCTCCAGCTCGACACCGGGCAGCTGCTGAAGATCGCGAAGAGAGGGGGAGTAACAGCGGTAGAGGCAGTG
CACGCCTGGCGCAATGCGCTCACCGGGGCCCCCCTGAACCTGACCCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGG
CAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTA
TCGCCAGCAACATTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACT
CCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTG
CCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGC
GGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACAATGGCGGCAAGCAA
GCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAG
CAACATTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACC
AAGTGGTGGCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGAC
CATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCCACGATGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTT
GCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGCGCTCG
AAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACGGT
GGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCCGGACCAAGTGGT
GGCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCC
TGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTG
CTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCAAGCAAGCGCTCGAAACGGT
GCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATCGCCAGCAACATTGGCGGCA
AGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACTCCGGACCAAGTGGTGGCTATC
GCCAGCAACATTGGCGGCAAGCAAGCGCTCGAAACGGTGCAGCGGCTGTTGCCGGTGCTGTGCCAGGACCATGGCCTGACCCG
GACCAAGTGGTGGCTATCGCCAGCAACGGTGGCGGCAAGCAAGCGCTCGAAAGCATTGTGGCCCAGCTGAGCCGGCCTGATCC
GGCGTTGGCCGCGTTGACCAACGACCATCTGCTGGAACATCACCATCACCATCACTGA 
 
Appendix 1: Open reading frame of sequenced expression plasmid encoding the TALE_Pap2_NI. The light and 
dark blue marked codons will code for the repeat RVD NI. 
 
 
MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRG
IPTLLLFKNGEVAATKVGALSKGQLKEFLDANLAGSGSGERQHMDSPDLGTVDLRTLGYSQQQQEKIKPKVRSTV
AQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGP
PLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPD
QVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
NIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRL
LPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQ
VVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASN
IGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALESIVAQLSRPDPALAALTNDHLLEHHHHHH* 
 
Appendix 2: Amino acid sequence of TALE_Pap2 with RVD NI at position 7 and thioredoxin tag.  
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MSDKIIHLTDDSFDTDVLKADGAILVDFWAEWCGPCKMIAPILDEIADEYQGKLTVAKLNIDQNPGTAPKYGIRG
IPTLLLFKNGEVAATKVGALSKGQLKEFLDANLAGSGSGERQHMDSPDLGTVDLRTLGYSQQQQEKIKPKVRSTV
AQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALPEATHEAIVGVGKQWSGARALEALLTVAGELRGP
PLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPD
QVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIAS
HDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQA
LETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRL
LPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQD
HGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQ
VVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASN
NGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALESIVAQLSRPDPALAALTNDHLLEHHHHHH* 
 
Appendix 3: Amino acid sequence of TALE_Pap5 with RVD NI at position 7 and thioredoxin tag.  
 
 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYP
DHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV
YIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP
EATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQ
VVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASN
IGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQAL
ETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLL
PVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDH
GLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQV
VAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNI
GGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALE
SIVAQLSRPDPALAALTNDHLLEHHHHHH* 
 
Appendix 4: Amino acid sequence of TALE_Pap2 with RVD NI at position 7 and green fluorescent protein tag.  
 
 
MSKGEELFTGVVPILVELDGDVNGHKFSVSGEGEGDATYGKLTLKFICTTGKLPVPWPTLVTTLTYGVQCFSRYP
DHMKQHDFFKSAMPEGYVQERTIFFKDDGNYKTRAEVKFEGDTLVNRIELKGIDFKEDGNILGHKLEYNYNSHNV
YIMADKQKNGIKANFKIRHNIEDGSVQLADHYQQNTPIGDGPVLLPDNHYLSTQSALSKDPNEKRDHMVLLEFVT
AAGITLGMDELYKTLGYSQQQQEKIKPKVRSTVAQHHEALVGHGFTHAHIVALSQHPAALGTVAVKYQDMIAALP
EATHEAIVGVGKQWSGARALEALLTVAGELRGPPLQLDTGQLLKIAKRGGVTAVEAVHAWRNALTGAPLNLTPDQ
VVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASN
IGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQAL
ETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLPDQVVAIASNGGGKQALETVQRLLP
VLCQDHGLTPDQVVAIASHDGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHG
LTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGGGKQALETVQRLLPVLCQDHGLTPDQVV
AIASNGGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNIGGKQALETVQRLLPVLCQDHGLTPDQVVAIASNGG
GKQALETVQRLLPVLCQDHGLTPDQVVAIASNNGGKQALETVQRLLPVLCQDHGLTPDQVVAIASHDGGKQALES
IVAQLSRPDPALAALTNDHLLEHHHHHH* 
 
Appendix 5: Amino acid sequence of TALE_Pap5 with RVD NI at position 7 and green fluorescent protein tag.  
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Appendix 6: SAM (AdoMet) and synthesized analogs (AdoYnYn, 1b) are accepted by the Dam enzyme (EcoDam). 
λ-DNA is labeled by the Dam enzyme with SAM and cofactor 1b. In the reaction mix the concentration of the 
labeling enzyme was varied in equivalents of enzyme in respect to GATC recognition sites. The Dam transferase 
is self-expressed and not purchased by a custom provider to ensure a functional, SAM-free enzyme. After the 
labeling reaction, the mix analyzed by restriction digest. The assay was performed by the Elmar Weinhold group, 
RWTH Aachen. 
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Appendix 7: ESI-TOF MS analysis of unmodified oligonucleotide duplex of the Pap2 sequence context (oligos 
o900 and o1815). 
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Appendix 8: Model of TALE (light brown) with the RVD NI accommodating substituent 1b.(violet) Model was 
generated by Julia Jasper and Oliver Koch, TU Dortmund. 
 
 
Appendix 9: Model of TALE (violet) with the RVD NI accommodating substituent 1b.(orange) Model was 
generated by Julia Jasper and Oliver Koch, TU Dortmund. 
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Appendix 10: ESI-TOF MS analysis of N6-modified oligonucleotide duplex of the Pap2 sequence context (oligos 
o900 and o1815) by E. coli Dam methyltransferase with cofactor 1b. 
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Appendix 11: ESI-TOF MS analysis of N6-modified oligonucleotide duplex of the Pap2 sequence context (oligos 
o900 and o1815) by E. coli Dam methyltransferase with cofactor 1c. 
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9. Abbreviations 
A adenine 
6mA N6-methyl adenine 
6hmA N6-hydroxymethyl adenine (in RNA) 
6fA N6-formyl adenine (in RNA) 
AD activation domain 
Amp ampicillin 
ATP adenosine triphosphate 
AU arbitrary units 
BER Base Excision Repair 
bp base pair 
°C degree Celsius 
C cytosine 
5mC 5-methyl cytosine 
5hmC 5-hydroxymethyl cytosine 
5caC 5-carboxymethyl cytosine 
5fC 5-formyl cytosine 
N4mC N4-methyl cytosine 
CpG cytosine preceding guanine dinucleotide 
CRISPR clustered regularly interspaced short palindromic repeats 
CRD central repeat domain 
CTR C-terminal region 
D aspartic acid 
Dam deoxyadenosine methyltransferase 
DNA deoxyribonucleic acid 
gDNA genomic DNA 
DMT DNA methyl transferase 
dNTP deoxy ribonucleotide triphosphate 
ds double stranded 
E glutamic acid 
EMSA electromobility shift assay 
ESI-TOF Electrospray ionization time of flight 
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FLASH Fast Ligation-based Automatable Solid-phase High-throughput 
G guanine 
G glycine  
GFP green fluorescent protein 
GG golden gate cloning 
H histidine 
HD RVD HD 
His6 histidine tag 
I isoleucine 
K lysine 
L leucine 
Lrp leucine responsive protein 
LR last repeat 
meDIP methylated DNA immunoprecipitation  
mESC mouse embryonic stem cells 
min minutes 
ml milliliter 
mM millimolar 
mU milliunits 
MTase methyltransferase 
N asparagine 
NE RVD NE 
NG RVD NG 
ng nanogram  
NHEJ non-homologous end joining 
NI RVD NI 
NL RVD NL 
NLS nuclear localization sequence 
nM nanomole  
nm nanometer 
NN RVD NN 
nt nucleotide 
NV RVD NV 
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OD optical density 
oriC origin of replication 
Pap pyelonephritis associated pili  
PEX primer extension 
R arginine 
RM restriction-modification 
RNA ribonucleic acid 
gRNA guiding RNA 
rpm revolutions per minute 
RVD repeat variable di-residue 
S serine 
SAM S-adenosyl methionine 
SAH S-adenosyl homocysteine 
T Thymine 
TALEs transcription-activation-like effector 
TAMRA tetramethylrhodamine 
TET1 ten-eleven-translocase 1 
TDG thymine DNA glycosylase 
TRX thioredoxin 
TSS transcription starting site 
UHPLC-MRM-MS/MS ultra-high-performance liquid chromatography triple quadrupole mass 
spectrometry 
UPEC uropathogenic E. coli 
V valine 
V Volt 
W Watt 
ZF Zinc finger 
µg microgram 
µl microliter 
µM micromol 
 
Note: chemical abbreviations can be found in the section 6.1.8. 
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